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ABSTRACT 
Genome-Wide Association Analysis of Major Depressive Disorder and Its Related Phenotypes 
 
by 
Nagesh Aragam 
Major Depressive Disorder (MDD) is a complex and chronic disease that ranks fourth as cause 
of disability worldwide. Thirteen to 14 million adults in the U.S. are believed to have MDD and 
an estimated 75% attempt suicide making MDD a major public health problem. Recently several 
genome-wide association (GWA) studies of MDD have been reported; however, few GWA 
studies focus on the analysis for MDD related phenotypes such as neuroticism and age at onset 
of MDD. The purpose of this study is to determine risk factors for MDD, identify genome-wide 
genetic variants affecting neuroticism and age at onset as quantitative traits, and detect gender 
differences influencing neuroticism. 
 
Bivariate and multiple logistic regression analyses were performed on 1,738 MDD cases and 
1,618 non-MDD controls to determine phenotypic risk factors for MDD. Multiple linear 
regression analyses in PLINK software were used for GWA analyses for neuroticism and age at 
onset of MDD with 437,547 Single Nucleotide Polymorphisms (SNPs).   
 
Gender (OR: 1.43; 95% CI: 1.24 – 1.64) and a family history (OR: 2.88; 95% CI: 2.48 – 3.35) 
were significantly associated with an increased risk of MDD, which supports the findings of 
prior studies. Through GWA analysis 34 SNPs were identified to be associated with neuroticism 
(p < 10
-4
). The best SNP was rs4806846 within the TMPRSS9 gene (p = 7.79 x10
-6
). 
Furthermore, 46 SNPs were found showing significant gene x gender interactions for 
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neuroticism with p<10
-4
. The best SNP showing gene x gender interaction was rs2430132 (p = 
5.37x10
-6
) in HMCN1 gene. In addition, GWA analysis showed that several SNPs within 4 genes 
(GPR143, ASS1P4, MXRA5 and MAGEC1/2) were significantly associated with age at onset of 
MDD (p < 5x10
-7
).  
 
This study confirmed previous findings that MDD is associated with an increased prevalence in 
women (about 43% more compared to men) and is highly heritable among first degree relatives. 
Several novel genetic loci were identified to be associated with neuroticism and age at onset. 
Gender differences were found in genetic influence of neuroticism. These findings offer the 
potential for new insights into the pathogenesis of MDD. 
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CHAPTER 1 
INTRODUCTION 
Major depressive disorder (MDD) is a chronic disease whose epidemiology has been studied 
worldwide and clinically researched to understand its etiology, distribution, development, and 
available treatments. MDD is characterized by its defining features of marked and persistent 
depressive moods, appetite and weight changes, insomnia or hyperinsomnia, fatigue or loss of 
energy, feelings of excessive guilt or worthlessness, poor concentration and/or indecisiveness, 
recurrent thoughts of suicide or death, and psychomotor agitation or retardation (Boomsma et al., 
2008). MDD is distinct from normal sadness by its persistence for longer than 2 weeks, drug or 
alcohol dependence, and somatic diseases (Sullivan et al., 2009). The definition of MDD 
excludes other mental disorders such as, bipolar disorder, schizophrenia, and other 
schizoaffective disorders. MDD has been found to be comorbid with nicotine dependence 
(Cardenas et al., 2002), alcoholism (Miguel-Hidalgo et al., 2010), anxiety (Boomsma et al., 
2000), and other psychological problems. Those afflicted with MDD may suffer from the disease 
throughout their lifetime. An estimated 75% of MDD afflicted people suffer from its chronic 
status and have an increased risk of suicide.  
MDD is a complex disease that affects the lives of both the patients and their families. It is a 
major cause of disability worldwide, ranking 4
th
 according to a recent survey of global burden of 
disease; and estimated to become 2
nd
 by 2030 (Mathers & Loncar, 2006).  The prevalence 
estimate for MDD in the United States National Comorbidity Survey - Replication (NCS-R) 
sample is 6.7% for a 12-month period which is an estimated projection of 13.1 to 14.2 million 
U.S. adults suffering from MDD during a 12-month period (Kessler et al., 2005). It has been 
firmly established that the risk for MDD is partly genetic and family studies have found a 
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significantly higher prevalence of MDD among biological relatives of MDD cases (Sullivan, 
Neale, & Kendler, 2000). Despite the existence of a considerable amount of research on the 
epidemiology and the biological correlates of MDD, the etiology of MDD remains unknown. An 
important clue has been the familial tendency and the heritability of MDD which has led to a 
number of genome-wide linkage studies with the identification of over 100 candidate genes 
(Sullivan et al., 2008). 
 
Significance 
Genetic factors are important in the risk of MDD and heritability has been estimated at 35%-
40% (Kendler & Prescott 1999, Sullivan et al., 2000).  MDD is frequently associated with 
smoking (Husky et al., 2008), anxiety (Boomsma et al., 2000), marital problems (South & 
Krueger 2008), and other psychological problems (Wade, Bulik, Neale, & Kendler, 2000). 
Recent studies of MDD at the molecular and genetic levels provide increasing evidence linking 
disease phenotypes with both genes and environment factors. Jabbi and coworkers have 
reviewed data that supports a role of monoaminergic and other related genes in environmental 
adaptation to conclude that convergent approaches may be useful in the examination of genetic 
modulation of disease phenotypes (Jabbi, Korf, Ormel, Kema, & den Boer, 2008).  The current 
literature reveals that more sophisticated tools and methods are needed to understand the 
etiology, prevalence, and genetic significance of MDD (The Psychiatric GWAS Consortium 
Steering Committee, 2009).  
Morbidity and mortality from MDD are significant public health problems as highlighted by 
two Surgeon General Reports (U. S. Department of Health and Human Services, 1999; U. S. 
Public Health Service, 1999). The Surgeon General’s Reports point out that suicide, a tragic 
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consequence of MDD occurs in 10%-15% of patients previously hospitalized for depression 
(Angst, Angst, & Stassen, 1999). This mortality is three times greater than that reported for the 
general United States population (U. S. Public Health Service, 1999). 
MDD is a highly heritable medical disorder and it is clear that the genetic etiology of MDD 
is complex and multi-factorial. Studies have shown that gender is important to the course and 
outcome of MDD. Silverstein (1999) described gender differences in the prevalence of clinical 
depression and Lavretsky et al. (2004) reported on sex differences in brain structure in geriatric 
depression. The gender-specific rate of MDD found in community samples agrees with the 1.7:1 
prevalence of MDD reported for women vs. men (Marcus et al., 2005). Recently, Essau, 
Lewinsohn, Seeley, and Sasagawa (2010) studied gender differences in the developmental course 
of depression and found strong evidence for a female preponderance of MDD in adolescence and 
adulthood. Immunoreactivity of cortical receptor proteins (NUDR and 5-HT1A) found in female 
subjects with MDD by Szewczyk et al. (2009) was lower compared to their male cohorts.  
Genetic and environmental factors may interact in their contribution to the risk of clinical 
depression such as Major Depressive Disorder in adolescents and adults. As stated above, MDD 
frequently coexists with smoking, anxiety, and other psychological problems. There has been 
little effort to examine gender and genetic risks together. Genetic and gender interaction may 
explain previously observed discrepancies between studies looking at candidate environmental 
agents and genes for MDD. Without accounting for these interactions the true main effects of 
either the gender factor or the gene will not be identified. One strategy for increasing the 
statistical power to detect MDD genes is to divide the phenotype into genetically meaningful 
subtypes (also called endophenotypes) and use a sufficiently large sample size of the population 
under study to decrease heterogeneity. 
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Another strategy was proposed by Risch and Merikangas (1996) in their analysis of the 
statistical power of linkage and association studies. By having a large number of genome-wide 
Single Nucleotide Polymorphisms (SNPs) a case-control association study may be conducted to 
associate specific SNPs and genomic regions with complex disease traits. Back in 1996, the 
human genome had not yet been sequenced, but the hypothesis of Risch and Merikangas laid the 
foundation for the genome-wide association studies that became a reality after 2004 when the 
functional human genome was fully sequenced. 
Identification of specific genes and gene x gender interactions may point to identifying 
specific population subgroups at increased risks for MDD. The findings have the potential to 
help with understanding the genetic associations, predicting the risk, and developing treatments 
for MDD. Increased understanding of how genetic factors and gender interact to alter the risks 
for depression may allow us to provide new targets for therapy. Identifying genes that may 
control the AAO of MDD would contribute to the understanding of MDD development and 
progression and allow therapeutic interventions for delaying the onset of MDD for specific 
families and population subgroups. 
 
Research Purpose 
The purpose of this research is to conduct Genome-Wide Association (GWA) analyses of 
MDD affection, related phenotypes (e.g., neuroticism, anxiety), and age at onset (AAO) of 
MDD.  
 
Research Questions 
This study addresses the following three research questions: 
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1. Are gender and family history significantly associated with an increased risk of major 
depressive disorder (MDD)? 
2. Is neuroticism (a measurable, quantitative trait) a useful indicator of major depressive 
disorder and are there any gene x gender interactions present? 
3. Do the genetic components of age at onset help us to understand development of 
major depressive disorder? 
 
Research Hypotheses 
Hypothesis 1 
Being female, smoking, and family history of MDD are three of the strongest risk factors for 
the development of MDD in the sample of European population from the Netherlands.  
Rationale. With the availability of phenotypic information from a sizeable number of MDD 
cases and non-MDD controls with 1,150 men and 2,206 women, carrying out statistically 
meaningful linear and logistic regression analyses with a binary outcome as MDD affection for 
multiple logistic regression analysis and a continuous quantitative outcome for multiple linear 
regression analysis must be straightforward. In addition, with data available for a total of 10 
predictors for depression, meaningful and strong asymptotic associations from the linear and 
logistic regression would pare down the number of possible risk factors for MDD. 
Hypothesis 2 
Neuroticism as a continuous variable may increase statistical power of genome-wide 
association analysis, and gender differences may exist in the genome-wide analysis of 
neuroticism. 
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Rationale. Neuroticism as an endophenotype for Major Depressive Disorder (MDD) is a 
well-known, measurable, genetic, and environment-dependent mental condition. While 
neuroticism has been recognized as one of the endophenotypes of MDD, few genome-wide 
analyses of neuroticism as a quantitative trait have been reported to date. Neuroticism, as has 
been conceptualized by Eysenck and Eysenck (1975), Hirschfield et al. (1983), and Pervin and 
John (1990), is a personality trait that reflects emotional instability, vulnerability to stress, and 
being anxiety prone. Neuroticism is considered as a moderate risk factor for major depression 
disorder (MDD) and as a quantitative personality trait, neuroticism is moderately heritable 
(Calboli et al., 2010).  According to Bienvenu et al. (2001) neuroticism is the strongest predictor 
of comorbidity of MDD.  
Hypothesis 3 
Age at onset as a quantitative trait may aid the identification of novel genetic variants for the 
development of MDD.  
Rationale. Although some genome-wide association studies of major depression disorder and 
related comorbidity traits such as smoking, alcoholism, and neuroticism have been reported, few 
studies have focused on the age at onset (AAO) of MDD. Luby (2009) asserts that empirical 
evidence for clinical depression in children as young as age 3 has recently been validated. Other 
studies have reported Traumatic Brain Injury (TBI) at an early age has led to higher rates of 
major depression within 3 months of injury (Rao et al., 2010). Kovacs and Lopez-Duran (2010) 
report that a compelling body of literature indicates that depressive symptoms in youngsters 
predict subsequent MDD. Also, a Turkish study (Bilgi et al., 2010) suggests small frontal gray 
matter volume leading to first-episode depression. However, few genome-wide studies in 
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literature have reported on the analysis of age at onset of major depression. 
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CHAPTER 2 
LITERATURE REVIEW 
Major depressive disorder (MDD) is a widespread and common mental condition that affects 
persons of all cultures, races, genders, and ages (Millon, 2004).  Both genetic and environmental 
factors influence the occurrence of MDD. MDD has been diagnosed using several approaches 
and instruments, and these are constantly undergoing revisions and refinements (Kessler et al., 
2009). 
The Diagnostic Interview Schedule (DIS) was one of the first instruments used to 
epidemiologically study MDD (epidemiology catchment area (ECA) study by Kessler et al., 
1994). Currently, a standard instrument for measuring MDD is the World Mental Health (WMH) 
Survey Initiative Version of the World Health Organization’s (WHO) Composite International 
Diagnostic Interview (CIDI) (Kessler & Ustun, 2000). The first nationally representative survey 
in the U.S. was conducted from 1990 to 1992 using a modified version of CIDI and a survey 
method (using face-to-face interviews) similar to ECA. This survey is known as the National 
Comorbidity Survey (NCS). A revised version of this survey (NCS-R) based on International 
Classification of Diseases, 10
th
 Revision (ICD-10) and Diagnostic and Statistical Manual of 
Mental Disorders, Fourth Edition (DSM-IV) was reported by Kessler et al. using data from face-
to-face interviews by professional interviewers from the Institute for Social Research at the 
University of Michigan, Ann Arbor, between February 2001 and April 2003 (Kessler et al., 
2005). The diagnostic criteria used by instruments like CIDI are based on the DSM-IV published 
by the American Psychiatric Association (APA). DSM diagnostic criteria are actively 
undergoing revisions (an updated DSM-V was recently announced by APA) (Regier, 2009) and 
is expanding to include newer diagnostic elements for such conditions as autism. In their study, 
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“Epidemiology of major depressive disorder: Results from the NCS-R”, Kessler et al. report that 
the prevalence estimates for CIDI/DSM-IV MDD in the total NCS-R sample (N = 9282) are 
16.2% (95% CI, 15.1 – 17.3) for lifetime and 6.6% (95% CI, 5.9 – 7.3) for the 12 months before 
the interview (Kessler et al., 2003).  
Further details of lifetime prevalence of Major Depressive Disorder and Age at Onset 
distributions as determined by the Kessler et al. (2003) study are given in Appendix A1 for the 
interested reader. 
 
Major Depressive Disorder and Related Phenotypes 
Kessler and Ustun (2000) classify mental disorders under five categories as follows –  
1. Mood, which includes major depression, neuroticism, bipolar disorder, and mania. 
2. Anxiety, which includes panic disorder, phobias like agoraphobia, generalized 
anxiety disorder, posttraumatic stress disorder (PTSD), and obsessive-compulsive 
disorder (OCD). 
3. Substance abuse, which includes alcohol abuse and dependence and nicotine 
addiction. 
4. Childhood-related, which includes attention-deficit hyperactivity disorder (ADHD), 
conduct disorder, separation anxiety disorder, and oppositional-defiant disorder. 
5. Others, which include eating disorders, premenstrual disorder, intermittent explosive 
disorder, pathological gambling, etc. 
Specific details regarding the diagnosis of the above mentioned mental disorders including 
screening for signs and symptoms, discussion of lifetime reviews, risk factors, treatment, etc. are 
discussed further in Kessler and Ustun (2000). The complete WMH-CIDI includes a screening 
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module, 40 modules focusing on diagnoses, functioning, treatment, risk factors, socio-
demographic correlates, and methodological factors. In addition, elaborate CDROM-based 
training materials are available to teach interviewers to administer the tests and to teach the 
administrators how to ensure the quality of data collected. An overview of the WMH-CIDI 
development is presented in Appendix A2. 
As is consistent for other complex disease traits, MDD shows strong evidence of heritability; 
however, identification of the causal genes for MDD has not yet been successful. Results from 
genome-wide linkage scans for MDD and related quantifiable personality traits show a 
relationship with “harm avoidance” and “neuroticism”. Regions on chromosomes 1, 4, 5, 7, 8, 
11, 12, and 13 show significant linkage signals, but, these findings have not been replicated 
among other populations (Boomsma et al., 2008). Neuroticism, Index of Depressive 
Symptomatology, and Beck’s Anxiety Disorder Inventory have all been found to be quantitative 
traits for MDD. Neuroticism is a personality trait that reflects emotional instability, vulnerability 
to stress, and being anxiety prone (Eysenck & Eysenck, 1975; Hirschfield, Klerman, Clayton, & 
Keller, 1983; Pervin & John, 1990). Neuroticism is moderately heritable and is considered to be 
a moderate risk factor for MDD (Calboli et al. 2010) and is the strongest comorbid predictor of 
MDD (Bienvenu et al., 2001). Fanous, Gardner, Prescott, Cancro, and Kendler (2002) have 
examined the genetic and environmental sources of covariation between neuroticism and MDD 
but were not able to identify a significant gender difference. Hettema et al. (2006) have sought to 
identify additional etiologic factors that contribute to the comorbidity of neuroticism with MDD. 
Their findings show substantial, if not complete, overlap between the genetic factors that 
influence individual variation in neuroticism and those that increase liability across the 
internalizing disorders. 
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Major Depressive Disorder Affection as a Binary Outcome 
In this study, MDD is considered as a binary outcome (i.e., Affected or Not Affected) that 
has related phenotypes (or risk factors) that are both categorical (e.g., married or single or 
widowed; smoking or non-smoking) and continuous (e.g., neuroticism and age at onset). 
Risk Factors of Major Depressive Disorder 
The phenotypes, gender, marital status (living with a partner is considered as being married), 
smoking status, alcohol use, and family history of depression are either binary or categorical and 
require little further explanation. Age and Age at Onset are continuous variables taking values of 
10-90 years depending on the specific population being used in a study.  
The phenotypes determining the traits of neuroticism, anxiety severity, depression 
symptomatology, and age at onset are further described as follows. Neuroticism is considered as 
a personality trait associated with several mental disorders and is considered as a risk factor for 
the development of MDD, anxiety disorders, and dementia (Calboli et al., 2010). A widely used 
measure for neuroticism is the NEO personality inventory (Costa & McCrae, 1992) which 
measures the following five dimensions of personality – Neuroticism, Extraversion, Openness, 
Agreeableness, and Conscientiousness (also collectively known as NEO-Five Factor Inventory 
or NEO-FFI). A score based on the subject’s response to a 5-point scale (‘strongly disagree’ to 
‘strongly agree’) for each of the dimensions of personality in a 60-item questionnaire is totaled to 
give a total score called the NEO-FFI total score (Guerrera et al., 2005). This continuous variable 
is then used to determine along with other predictor variables (e.g., Inventory of Depressive 
Symptomatology and Beck’s Anxiety Inventory scores) a binary predictor variable that is used as 
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the outcome - the MDD affliction status (i.e., affected / not affected) for use in logistic regression 
analyses of MDD. 
The inventory of depressive symptomatology (IDS) is a 30-item questionnaire designed to 
assess (and often quantify the severity of) depressive symptoms. The assessment uses all the 
criterion symptom domains designated by the American Psychiatry Association (APA) 
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) (APA, 1994). The time frame 
for assessing the symptom severity is 7 days prior to the day of assessment. The Beck Anxiety 
Inventory (BAI) is a 21-question multiple choice inventory created by Aaron T. Beck used for 
measuring the severity of an individual’s anxiety level (Leyfer, Woodruff-Borden, Klein-
Tasman, Fricke, & Mervis, 2006). Each question in the inventory has one answer out of four 
(‘not at all’, ‘mildly’, ‘moderately’, and ‘severely’) with a point system coding each category. 
For example, the answer ‘not at all’ scores 0-7 points, while the answer ‘severely’ scores 26-63.  
Other MDD related phenotypes such as Age at Onset (AAO) of MDD, Anxiety Severity, 
Depression Severity, and Neuroticism are defined below and their descriptive characteristics are 
described later in chapter 3.  
 Age at onset is defined by Composite Interview Diagnostic Interview (CIDI) (Kessler 
& Ustun, 2000) as the age when the first of the 2 years or longer a subject felt sad or 
depressed.  
 Depression Severity is defined by the Inventory of Depressive Symptoms as a total 
score computed by summing the 28 items symptom list in the CIDI interview.  
 Anxiety Severity is defined by the Beck Anxiety Inventory which is a total score 
computed by summing the 21 items symptom list in the CIDI interview.  
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Brief Survey of Major Depressive Disorder Phenotypic Studies 
The psychiatric and psychopathologic literature is abundant with phenotypic studies of MDD 
focusing on gender difference (e.g., Goodwin & Gotlib, 2004; Hakamata et al., 2009; Hyde, 
Mezulis, and Abramson, 2008; Parker & Hadzi-Pavlovic, 2004; Silverstein, 1999), marital 
problems and/or partner violence (e.g., Shorey et al., 2011; South & Krueger, 2008), smoking 
status (e.g., Cardenas et al., 2002; Gulec et al., 2005), family history (Lazary, Gonda, Benko, 
Gacser, & Bagdy, 2009), and alcohol use (e.g., Miguel-Hidalgo et al., 2010). Each of these MDD 
phenotypes has been researched well, and the following subsections briefly summarize the 
previous work. 
The reported heritability of neuroticism is equal or greater than heritability estimates for 
MDD (Calboli et al., 2010). The heritability of neuroticism has been estimated at 0.30 – 0.50 
based on twin studies (Birley et al., 2006; Bouchard & Loehlin, 2001; Floderus-Myrhed, 
Pederson and Rasmuson, 1980; Jang, Livesley & Vernon, 1996; Martin et al., 2000) along with 
genetic covariance with depression and anxiety (Jardine, Martin, & Henderson, 1984; Fanous et 
al., 2002; Hettema, Prescott, & Kendler, 2004; Hettema, Neale, Myers, Prescott, & Kendler, 
2006; Huezo-Diaz, Tandon, & Aitchison, 2005; Kendler, Neale, Kessler, Heath, & Eaves, 1992, 
1993). A link between genotype and personality has been tried to be established by several 
researchers using NEO PI-R facets. For example, Persson et al. (2000) have shown an 
association between a polymorphism in the tyrosine hydroxylase gene and personality traits, but, 
Tochigi et al. (2006) report that they could not confirm the association with the tyrosine 
hydroxylase gene. However, in a classic study by Lesch et al. (1996) a relationship between the 
serotonin transporter gene regulatory region (5-HTTLPR) and neuroticism has been found. 
Furthermore, it was found that individuals with a shorter allele version of the gene had higher 
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neuroticism scores and was significant for both heterozygous and homozygous versions of the 
allele. The authors further predict that approximately 10 to 15 genes in the 5-HTTLPR region 
might be implicated in the moderation of neuroticism scores (Lesch et al., 1996). 
Gender Difference and Major Depressive Disorder 
The importance of gender on the course and outcome in MDD has been widely 
acknowledged. For example, Silverstein (1999) described the gender difference in the prevalence 
of clinical depression, while Lavretsky et al. (2004) reported sex differences in brain structure in 
geriatric depression. The gender-specific rate of MDD is proportional to rates found in 
community samples with a 1.7:1 prevalence of MDD in women vs. men (Marcus et al., 2005). 
Recently Esau et al. (2010) studied the gender differences in the developmental course of 
depression. Especially, gender-specific associations of NUDR and 5-HT1A receptor proteins with 
MDD were reported by Szewczyk et al. (2009).  
Hyde et al. (2008) in trying to find an integrated model of affective (emotional reactivity), 
biological (genetic vulnerability, pubertal hormone, timing, and development) and cognitive 
(cognitive style, objectified body consciousness, and rumination) have summarized the state-of-
the-art in gender differences for MDD. Accordingly, several factors can be attributed to the 
higher prevalence of MDD in girls than boys and in women than men as follows – 
 Greater ruminative coping (Nolen-Hoeksema & Girgus, 1994) 
 Dependence on relationships or affiliative needs (Cyranowski, Frank, Young, & 
Shear, 2000) 
 Ovarian and adrenal hormonal changes in puberty (Goodyer, Herbert, Tamplin, & 
Altham, 2000) 
 Genetic factors (Kendler et al., 1993; Zubenko et al., 2002) 
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 Body dissatisfaction (Nolen-Hoeksema & Girgus, 1994) 
 Greater cognitive vulnerability (Hankin & Abramson, 2001) 
 Exposure to negative life events like rape and child sexual abuse (Kendler, Gardner, 
& Prescott, 2002) 
 Gender intensification and adherence to traditional gender roles (Aube, Fichman, 
Saltaris, & Koestner, 2000) 
 Interactions among the above listed factors (Hankin & Abramson, 2001). 
While an in-depth summary of each of the above study is beyond the scope of this report, 
suffice is it to say that the female gender has specific biological and cognitive factors that are 
unique to the gender and thus the manifestation of higher prevalence of MDD in females does 
not seem to be unnatural. In particular, the social factors like body image, traditional role playing 
(this would especially be true in Asian and Mid-eastern cultures), and lack of access to equal 
rights (e.g., to education) may breed gender differences right from the moment of birth for girls 
and women.  
According to Essau et al. (2010) the greatest increase in gender difference occurs between 
the ages of 15 and 18 and the underlying mechanisms for this are not clear. It seems to generally 
reflect the interplay of gender socialization, hormonal changes, and stressful life events 
associated with adolescence (Cyranowski et al., 2000). Thus Essau and coworkers who studied 
the developmental course of MDD in a project (Oregon Adolescent Depression Project) with 773 
participants concluded that childhood depression may be a more serious risk factor for girls than 
boys. 
More interestingly however, Szewczyk et al. (2009) point to some basic biological reasoning 
in terms of the gender-specific alterations in cortical NUDR protein receptor gene. Female 
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subjects with MDD in their study had reduced protein expression of NUDR and 5-HT1A 
receptors in the prefrontal cortex. Thus, they attribute biological factors for higher prevalence of 
MDD in females.  
Thus it seems that both social and biological factors play a big role in understanding the 
gender differences and prevalence of MDD in girls and women. This area of understanding the 
1.7:1 prevalence of MDD in women has become a prime target with researchers in psychology, 
psychiatry, molecular biology, and epidemiology.  
Smoking Status and Major Depressive Disorder 
Husky et al. (2008) conducted an epidemiological study to determine whether smoking 
behavior was associated with MDD, and further if the association was greater in women. They 
used data from the National Epidemiologic Survey on Alcohol and Related Conditions 
(NESARC). The details of data collection and the sample are published elsewhere (Grant et al., 
2003). Relationships between smoking status (categorized as daily, occasional, prior) and DSM-
IV MDD by gender were assessed in terms of odds ratios using logistic regressions. The results 
showed that women with prior smoking were at significantly higher risk of current and past 
MDD than men (OR: 1.53 vs 1.36; 1.72 vs 1.36). Similarly, the results for current occasional – 
the ORs were 1.92 vs 1.39; 1.9 vs 1.3; and for daily smoking – the ORs were 2.52 vs 1.95; 1.84 
vs 1.48. 
MDD and nicotine dependence are highly comorbid (Cardenas et al., 2002). It seems that the 
MDD patients may use nicotine to ameliorate their depressive symptoms. Cardenas et al. 
hypothesized that a dysfunctional brain reward system (BRS) might link the use of nicotine and 
MDD neurobiologically to enhance the dopaminergic activity. So they conducted a double-blind 
case-control study with 34 subjects (18 nicotine-dependent cases and 16 nicotine-independent 
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controls) to assess their hypothesis. The results were mixed in the sense that the nicotine (or 
smoking) did not modify the response to d-amphetamine in either cases or controls, but it 
decreased the overall negative mood state during placebo sessions. The researchers concluded 
that although the BRS may be dysfunctional in MDD cases, chronic nicotine use does not modify 
response to d-amphetamine. In my personal opinion, the sample size (34) was too small to be 
able to conclude anything definitively. 
In another cross-sectional study of association between smoking and depressive symptoms in 
Turkey the researchers found the smokers among medical students were 2.2 times more likely to 
have depressive symptoms than nonsmokers (Gulec et al., 2003).  
Family History and Major Depressive Disorder 
As stated earlier, MDD has been shown to have a heritability of almost 40% (Kendler & 
Prescott, 1999). MDD as an affective disorder has been shown to be both inherited and 
influenced by environmental factors such as living in a household with diagnosed MDD cases 
(Lazary et al., 2009). However, sufficient knowledge concerning inherited background and how 
the environmental factors moderate the onset of MDD is still unknown. Lazary and coworkers 
studied how affective temperaments (AT) and affective family history (AFH) relate to depressive 
symptoms in a general population. They used 501 Hungarian adults to measure and analyze the 
mediation of AT in AFH groups. Not surprisingly, a critical part of inherited factors of 
depression is mediated by affective temperaments. The probability of having dominant 
temperament was more than two-fold in the group with AFH than one without. 
ATs are hypothesized to be associated with phenotypic expression of affective disorders 
(Whittle, Allen, Lubman, & Yucel, 2006) and their relevance to endophenotype studies has also 
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been proposed (Gonda et al., 2006). But much remains to be done in this area to fully understand 
the role of family history in the development of MDD and other depressive disorders. 
Marital Problems and Major Depressive Disorder 
South and Krueger (2008) opine that marital distress may exert influence on MDD by acting 
as a stressor. They conducted a study of marital quality on a range of mental disorders (including 
symptoms for MDD) in 379 twin pairs concordant for marriage.  A phenotypic factor analysis 
was first conducted to confirm that one factor best accounted for the variance shared between 
MDD and other mental disorders. Then they investigated the overlap between genetic and 
environmental influences on both marital quality and internalizing spectrum to find genetic 
influences common to both phenotypes. Their conclusion was that those with a genetic 
predisposition to internalizing syndromes may be more likely to express the predisposition in 
context of a dissatisfying marriage. 
Alcohol Use and Major Depressive Disorder 
Miguel-Hidalgo et al. (2010) studied MDD and alcohol use in a more clinical context by 
measuring the levels of excitatory amino acid transporters (EAATs) 1 and 2 in a case-control 
experiment. Their results show that the EAAT2 immunoreactivity was significantly lower in 
MDD cases than in controls as were the levels of EAAT1. Their clinical conclusion is that there 
are differential changes in the expression of glial glutamatergic markers in depression and 
alcoholism suggesting a depletion of certain aspects of glutamatergic processing in MDD cases. 
Thus alcohol may influence MDD through complex processes in the prefrontal cortex that are 
still unknown. 
Interestingly enough, Nurnberger, Jr. et al. (2001) have found evidence using genome-wide 
sibling-pair linkage analysis of comorbid alcoholism and MDD to conclude that certain genes 
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may influence both predisposition to alcoholism as well as detrimental diseases like MDD. They 
evidence a specific locus (or a genetic marker) on chromosome 1 that is responsible to this dual 
vulnerability. This was a part of the collaborative study on the genetics of alcoholism from the 
National Institute on Alcohol Abuse and Alcoholism and the data from this study were used to 
test three phenotypes – comorbid alcoholism and depression, alcoholism or depression, and just 
depression. It is also worth noting in the Nurnberger et al. study that a majority of subjects with 
alcoholism problem in this data set were men and a majority of subjects with depression were 
women. Thus, the study may have limitations with confounding effects along with interactions 
between alcoholism and depression. 
However, some epidemiological studies have also shown researchers the positive effects of 
coping with MDD by using moderate alcohol consumption and the comorbidity of alcohol use 
and MDD needs to be researched further to elucidate our understanding of alcoholism as a 
predictor or risk factor of MDD. 
 
Genetic Studies of Major Depressive Disorder and Related Phenotypes 
Before the human genome was completely sequenced, genetic studies took the form of 
family, twin, linkage, and association studies that dealt with how genetic information was 
transmitted and inherited down through generations of affected patients of a disease to be 
studied. Most often these diseases were non-Mendelian, complex, and chronic diseases like 
Alzheimer’s, Parkinson’s, Major Depression, etc. The main thrust of these genetic studies was to 
figure out how diseases are carried through genetic markers and how studying the genes of 
immediate family members like twins, parents and children, and siblings might show patterns of 
disease linked genes in specific genetic regions and how they get inherited via strong linkages on 
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specific chromosomes. An excellent overview of these genetic studies is given in “Statistical 
Genetics: Gene Mapping through Linkage and Association” by Neale, Ferreira, Medland, and 
Posthuma (2009). 
A brief review of genetic linkage and association studies of MDD and its phenotypes in the 
literature is given below. For detailed discussion of any one method or one phenotype linkage 
mapping across an individual family genome or inheritance patterns, the reader is referred to a 
plethora of information available in the PubMed. We discuss a sample of representative family 
studies, linkage studies, and association studies of MDD below. 
Genetic Family studies of Major Depressive Disorder 
To explore the continuities and discontinuities between MDD in children and adolescents and 
MDD in adults, Klein, Lewinsohn, Seeley, and Rhode (2001) use family studies. In their study of 
268 adolescents with a history of MDD, 110 adolescents with non-MDD disorders, and 291 
adolescents with no history of mental disorders they found evidence of familial aggregation of 
adolescent MDD. They also found considerable specificity in the pattern of familial 
transmission. 
They used hazard ratios (HRs) to measure the increased risk for family members of a MDD 
afflicted patient and they found the following – 
 Elevated rates of MDD (HR: 1.77, 95% CI: 1.46 – 2.31) 
 Dysthymia (HR: 1.79, 95% CI: 1.11 – 2.87) 
 Alcohol abuse or dependence (HR: 1.29, 95% CI: 1.05 – 1.53) 
This pattern of MDD transmission within families was also found for other mental disorders 
like anxiety disorder, substance abuse, and antisocial behavior. 
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According to the literature available on family studies and MDD, it seems that the heritability 
poses almost a three-fold increase in risk (2.84) according Sullivan et al. (2000). However, it has 
also been established that families share MDD along with other phenotypic manifestations such 
as mood disorders (esp. bipolar), schizophrenia, and neuroticism. Golster-Dubner, Galili-
Weistubb, and Segman (2010) criticized that a family-based association study of MDD may not 
pick up large genetic effects for MDD. They make the point that MDD coexists in families with 
other mental disorders like schizophrenia, bipolar disorder, and neuroticism, and thus any family 
association of MDD may be only small and overlapping with other mental disorder effects.  In 
addition, two separate studies (Liu et al., 2009; Serretti et al., 2003) trying to link specific genes 
(BDNF) and specific enzymes (e.g. tyrosine hydroxylase) that are known to have a role in 
depression within a family failed to produce family-based associations. This might be due to the 
small genetic effects mentioned earlier for MDD and the fact that the specific etiology of family 
inheritance of MDD is still largely unknown. 
Genetic Linkage Studies of Major Depressive Disorder 
Genetic risk factors are well established for MDD and a twin study has indicated >70% 
heritability in twins (McGuffin, Katz, Watkins, & Rutherford, 1996). Genome-Wide linkage 
analysis was carried out by McGuffin et al. (2005) in a sample of 497 sib pairs concordant for 
recurrent MDD. The study found linkages on chromosomes 1, 12, and 13 at 1p36, 12q23.3 – 
q24.11, and 13q31.1 – q31.3 respectively, while implicating genes MTHFR and DAO. The 12q 
region has already been implicated with other mental disorders like schizophrenia and bipolar 
disorders and the 13q region has been linked to panic disorders. A previous report of a locus on 
15q also showed genome-wide significance for recurrent depression and the current 12q findings 
are also genome-wide significant. 
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In 2003 Zubenko and his team of coworkers used the genome-wide linkage studies to report 
genetic loci influencing the recurrent early-onset MDD (RE-MDD) (Zubenko et al., 2003). This 
study found 392 highly informative polymorphisms with an average spacing of 9 cM in the 
region of the CREB1 gene. Nineteen chromosomal regions contained linkage peaks and 10 
reached an adjusted p-value of < 0.001. Five loci showed evidence of interaction with the 
CREB1 locus, and the authors of the report concluded that genes whose products participate in 
cellular signaling pathways that converge on CREB region harbor alleles that affect the 
development of MDD. 
Holmans et al. (2004) conducted a study of genome-wide significant linkage to RE-MDD on 
the region of chromosome 15q using 297 informative families containing 415 independent 
affected sibling pairs and 685 informative relative pairs. All affected cases were diagnosed 
before the person turned 31, and the affected relatives had a mean AAO of 41 years. Genome-
Wide significant linkage was observed on chromosome 15q25.3-26.2 with an empirical genome-
wide p-value of 0.023. These findings indicate chromosome 15 as a strong candidate for further 
studies of MDD susceptibility. 
In a replication study Camp et al. (2005) used Utah pedigrees to identify loci that influenced 
RE-MDD and anxiety disorders. They used 87 large extended Utah pedigrees to investigate three 
phenotypes: RE-MDD and anxiety, RE-MDD or anxiety, and RE-MDD and anxiety. They 
replicated the earlier loci on 12q, 7p, and 18q and identified further interesting regions on 4q and 
15q. Their study suggests some overlapping genetic etiologies between MDD and anxiety 
disorder. 
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Candidate Gene Association Studies of Major Depressive Disorder 
Several candidate genes such as the CFH gene, the FTO gene, the TCF7L2 gene, and the 
IL23R gene have been shown to be associated with MDD (e.g., Boomsma et al., 2008). 
Increased risk for MDD has also been established in a study by Traks et al. (2008) which relates 
the MDD risk to IL20 and IL24 genes and suggest that cytokines may contribute to the 
pathogenesis of MDD. A recent study by Rietschel et al. (2008) has implicated the G72 gene 
with MDD and neuroticism in large population-based groups in Germany. More recently, Shyn 
and Hamilton (2010) have presented an intensive review. 
In a classic paper by Cordell and Clayton (2005), the authors discuss the rationale behind 
genetic association studies. Traditional epidemiologic studies of environmental risk factors and 
genetic studies have a lot of similarities, but there are issues specific to the studies of genetic risk 
factors (e.g. use of specific family-based designs), population history, and underlying genetic 
mechanisms. Genetic association differs from genetic linkage in that the alleles of interest will be 
the same across the whole study population while linkage allows different alleles to be associated 
with the disease trait in different families.  
Genetic associations can be direct or indirect, confounded or with interactions, consider 
direct relationship between genotype and phenotype, or it could be indirect relationship with the 
consideration of linkage disequilibrium. A brief literature review of the genetic associations of 
two of the MDD traits we have proposed to study (i.e., neuroticism and age at onset) is given 
below. 
Calboli et al. (2010) have found that neuroticism is a moderately heritable MDD trait and a 
risk factor for developing MDD. They performed a genome-wide association analysis of 2,235 
participants drawn from a large population-based study of neuroticism using 430,000 autosomal 
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SNPs together with 1.3 million imputed SNPs from the HapMap CEU samples (Gibbs et al., 
2003). They found that the gene NKAIN2 showed suggestive association (p < 10
-6
) with 
neuroticism as a main effect and the gene GPC6 showing evidence of interaction (p ≈ 10-7) with 
age. They found support for one previously associated association with the gene PDE4D but 
failed to replicate other recent finds. They concluded that common SNP variation does not 
strongly influence neuroticism. 
Brummett, Boyle, Kuhn, Siegler, and Williams (2008) examined prolactin responses to a 
tryptophan challenge as they relate to the Neuroticism, Extraversion, Openness, Agreeableness, 
and Conscientiousness (NEO Five Factor Inventory or NEO-FFI used to measure neuroticism 
quantitatively; described more fully in  2.1) using 67 volunteers. Their findings indicate that the 
gender moderated the association between neuroticism and prolactin level (p < 0.03) and higher 
levels of neuroticism were associated with decreased levels of prolactin responses in females; 
males responded exactly opposite, i.e., higher levels of prolactin produced higher levels of 
neuroticism. 
Lake, Eaves, Maes, Heath, and Martin (2000) examined the hypothesis that environmental 
transmission is a significant factor in individual differences for neuroticism among 45,850 
members of extended twin kinships from Australia (N=20,945) and the U.S. (N=24,905). They 
found no such evidence of environmental transmission influencing neuroticism levels in 
replicated samples from two different continents, concluding that a simple genetic structure 
underlies familial resemblance for the neuroticism trait. 
In a study of gene x environment interactions in mental disorders Tsuang, Bar, Stone, and 
Faraone (2004) state that association studies provide potentially useful approach to the detection 
of gene-environment interactions in mental disorders. They point to depression-like behaviors in 
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rats and various nonhuman protocols when they are exposed to environmental stress such as 
maternal separation, neglect, and social deprivation. However, the behavioral responses differ 
depending on the individual genetics and the interaction effects of the environment on the genes.  
Unlike neuroticism, the age at onset of MDD has not been explored under the umbrella of 
genetic association studies, especially in cases of early childhood depression in children as young 
as age 3 (Luby, 2009). However, the literature points to several linkage studies of recurrent, 
early-onset major depression (Camp et al., 2005; Holmans et al., 2004; Zubenko et al., 2003). 
These were discussed earlier under genetic linkage studies. Other genetic association studies of 
MDD involving specific genes such as 5-HTTLPR and IL-6 are discussed next. 
Myung et al. (2010) studied the serotonin transporter gene polymorphisms and chronic 
depression recurrence in Korean subjects using 252 patients with MDD. The patients were 
genotyped for s/l polymorphisms in 5-HTT promoter and s/l variation in the second intron of the 
5-HTT gene (5-HTT VNTR intron 2). Chronicity was associated with 5-HTTLPR where the l/l 
allele showed higher rate of chronicity than s/l or s/s varieties (OR: 4.45; 95% CI: 1.59 – 12.46; 
p = 0.005). Thus 5-HTTLPR was implicated in the association with MDD, while the 5-HTT 
VNTR intron2 was not. 
Uddin et al. (2010) studied epigenetic differences between patients with lifetime MDD and 
those without. They used a community-based sample in a Detroit neighborhood taken from a 
sample of participants in the Detroit neighborhood Health Study (DNHS). Their sample 
contained 33 persons with lifetime MDD and 67 persons without lifetime MDD. Bioinformatic 
analyses were performed on the genes uniquely methylated and unmethylated in each group and 
inflammatory biomarkers Interleukin 6 (IL-6) and C-reactive protein (CRP) were measured to 
investigate the possible significance of the methylation profile. Their conclusion was that 
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examining epigenetic mechanisms in concert with other dynamic markers of physiologic 
functioning could improve our understanding of neurobiology of depression.  
Lesch (2004) comprehensively studied MDD and the gene x environment interactions for 
MDD in a paper describing how starting from family studies and linkage studies the research has 
moved on to the genetic association studies of MDD. Investigation of subtle alterations in gene 
expression, correlations between genotype and brain activity and of environmental variables 
interacting with genetic variants have advanced research into the genetics of depression. He adds 
that gene-phenotype correlations have been substantiated by functional neuroimaging and the 
notion of gene networks that control brain development is increasingly recognized. However, 
given the etiologic and psychobiologic complexities of mental disorders, identification of 
specific genetic factors is extremely difficult and gene hunting continues. 
MDD like other complex genetic diseases is heterogeneous in origin and is polygenic where 
different susceptibility genes may be operating in different families. Thus the gene x 
environment interactions need to be fully evaluated before understanding the etiology of MDD 
and there is a need to investigate the molecular basis of MDD. This is discussed in the next 
subsection briefly. 
Molecular Basis of Major Depressive Disorder 
Jabbi et al. (2008) point out that there is growing evidence linking disease phenotypes with 
genes on one hand and the genesis of stress related disorders like MDD as a result of exposure to 
environmental pathogens on the other. They conclude that advocating the use of convergent 
approaches in examining the genetic modulation of disease phenotypes might be useful. Taking 
the example of MDD and a few well-known MDD associated genes (e.g., 5-HTT, MAOA, and 
COMT) the researchers explored the gene x gene interactions to find out how certain genetic 
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markers may result to endophenotypes like HPA axis dysfunction leading to susceptibility for 
some of the co-occurring neuropsychiatric disorders like MDD and neuroticism. They further 
point to such results as HPA-axis involvement in the maintenance of homeostasis during stress 
and a speculation of interaction between COMT and MAOA on peripheral endocrine 
responsivity to stress may be related to a combined influence of these genes affecting the CRH 
functioning. Thus understanding genetic associations at the molecular functioning level are 
needed to further understand MDD and the modulation of complex behavioral adaptations 
relevant for a disease phenotype. Further discussion of this topic is beyond the scope of this 
report. 
 
Genome-Wide Association Studies of Major Depressive Disorder 
Large-scale studies are needed with multiple phenotypes, DNA, and ideally, biological 
material that enables gene expression and other genomic and proteomic analyses. Genome-Wide 
analysis study is one such large-scale undertaking with data collected over several years in order 
to identify potential genes and genomic regions that are significant in patients diagnosed with 
cases of MDD. 
The conventional genome-wide association study (GWAS) approach is a hypothesis-free, 
systematic search of tagging Single Nucleotide Polymorphisms (SNPs) across the human 
genome to identify novel gene associations with common diseases and has emerged as a 
powerful tool to identify disease-related genes for many common human disorders and other 
phenotypes (Guessous, Gwinn, & Khoury, 2009; McCarthy et al. 2008; Wellcome Trust Case 
Control Consortium 2007). Recently, several GWAS of MDD have been reported. For example, 
Sullivan et al. (2009) reported the possible role for the presynaptic protein piccolo (gene PCLO); 
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Shyn et al. (2009) found strong associations for genes ATP6V1B2, SP4, and GRM7 from a 
meta-analysis; Garriock et al. (2010) found three SNPs within genes UBE3C, BMP7, and RORA 
associated with MDD with p-values less than 1 x 10
-5
; and Shi et al. (2010) found SNPs within 
the gene SP4. Also, shared genetic risks for MDD and bipolar disorder have been reported 
(McMahon et al., 2010).  
One of the first Genome-Wide Association (GWA) studies that examined gender differences 
for MDD is now published online (Aragam, Wang, & Pan 2011). That study identified 40 male-
specific and 56 female-specific MDD associated Single Nucleotide Polymorphisms (SNPs) with 
P-values less than 10
-4
. In addition, 38 SNPs showing gene x gender interactions influencing 
MDD (P < 10
-4
) were also found. The implicated genes in this study were LGSN, PCLO, FIGN, 
and OR4B1.  
A brief summary of Genomics and GWAS literature is provided in Appendix B for interested 
readers. 
 
Genome-Wide Association Studies of Neuroticism 
In earlier GWA studies, van den Oord et al. (2009) have reported finding potential 
association between the MAMDC1 gene and neuroticism, while Shifman et al. (2008) have 
found suggestive association between the PDE4D gene and neuroticism in one sample and 
replicated in another. However, replication in some other samples by Shifman et al. was not 
possible. Terraciano et al. (2010) found potential association signals for all five neuroticism 
scales, but the effect sizes were small and most associations failed to replicate in other samples. 
Several researchers have also reported an association of Neuroticism and Alzheimer’s disease in 
literature (Wang et al., 2009; Wilson et al., 2003). 
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    The differences in the quantitative trait scores for neuroticism in men and women have 
been found to moderate the prevalence of MDD in females. Recently some studies of 
neuroticism have been reported to identify gender differences in MDD severity as a function of 
neuroticism total score (Eaves, Heath, Neale, Hewitt, & Martin, 1998; Fanous et al., 2002; Lake 
et al., 2000; Liu et al., 2006) with the males showing consistently less severity than females 
(Jardine et al., 1984; Jorm, 1987). Other population and gender studies on neuroticism in the 
literature include, a twin study of the relationship between internalizing disorders and 
neuroticism (Hettema et al., 2006), association of serotonergic function with neuroticism being 
moderated by the gender (Brummett et al., 2008), neuroticism and dementia (Wang et al., 2009), 
and prospectively assessed neuroticism association with anorexia nervosa among Swedish twins 
(Bulik et al., 2006).  
 
Summary 
Literature about MDD as a psychiatric trait, or a disease phenotype, is well-known and has 
been studied for a number of years. MDD is heritable, runs in families, and is found to be 
comorbid with smoking and is more prevalent in women than in men. An elaborate international 
instrument (WMH-CIDI) has been developed to study MDD epidemiologically and is in wide 
use. MDD is a chronic disease by its own accord and should not be confused with other mental 
disorders like bipolar disorder and schizophrenia. Furthermore, it is conceptualized as a binary 
trait in this study although some experts argue otherwise.  
Of late MDD is being studied as a complex genetic disease, and researchers are looking to 
conduct genome-wide studies to understand and elucidate the genetic variants of this chronic 
disease. Although strong correlations exist between neuroticism and MDD, few studies have 
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looked at neuroticism as an endophenotype of MDD. Linkage and family studies have been 
conducted widely in the past to unearth several genetic variants of MDD, but the implicated 
genes have only been attributed to have small effects. Lately genome-wide studies have begun 
with the availability of large amounts of genotype information and SNP data from selected 
samples of MDD patients. 
Genome-Wide association analysis is gaining ground as an attractive hypothesis-free 
approach to study complex genetic diseases such as MDD. Although neuroticism and family 
risks (i.e., being a first degree relative of someone who has been diagnosed with MDD) are 
known predictors, few genome-wide studies using neuroticism and age at onset have been found 
in the literature. In this proposed research study, both neuroticism and age at onset via inheriting 
specific genes are studied to explore genome-wide association of MDD in a specific subset of 
human population representative of the people with a European origin. 
Determining the use of endophenotypes of MDD (e.g. neuroticism) as quantitative traits to 
find the genetic variants of MDD and to find out how the analysis of age at onset of MDD as a 
quantitative trait may help to understand the prevalence and severity of MDD lays the foundation 
for this research work. A major goal of our study is that the study results will provide a genetic 
basis for the elucidation of MDD and its phenotypes for future studies that examine other 
populations. 
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CHAPTER 3  
MATERIALS AND METHODS 
The overall goal of this research study is to understand and investigate the epidemiology and 
underlying genetic basis for the onset, prevalence, and the chronic suffering (e.g., 12-month 
disease burden, being disposed to such comorbidity as neuroticism) of those with major 
depressive disorder (MDD). The following sections describe details of data sets and study 
participants used for this research. A detailed study plan is also presented. 
 
Datasets 
The two data sets used in this research are briefly described below - 
#1 GAIN Sample  
This dataset is a combination of samples from the Netherlands Study of Depression and 
Anxiety (NESDA) and the Netherlands Twin Registry (NTR). These data are available from the 
public database of National Center for Biotechnology Information (NCBI), known as dbGaP. 
Briefly, the data were collected from two longitudinal studies between 1991-2004 that used 
clinical interviews, demographic questions, and biobanking home visits. Data collection for the 
NESDA study was from 1996–2004 and for the NTR was from 1991-2004. There are 3,741 
records in the combined NESDA and NTR data of which 1,991 records show a diagnosis of 
MDD.  
In 2006 a consortium of researchers from the University of North Carolina at Chapel Hill 
(UNC-CH), Virje University in Amsterdam, and the Universities in Groningen and Leiden were 
selected to genotype the combined NESDA and NTR samples in order to conduct a GWAS of 
major depression. This study of MDD by the consortium of researchers came to be known as one 
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of the six Genetic Association Information Network (GAIN) studies. The GAIN initiative is a 
part of a public-private partnership of the Foundation for the National Institutes of Health Inc. 
The funding for this initiative came from three pharmaceutical companies – Pfizer, Affymetrix, 
and Abbott Laboratories. Not all 1991 NESDA cases were selected for the GAIN study and a 
few of the non-MDD controls were added from the NESDA sample. Thus the combined NESDA 
and NTR sample consists of 1,738 MDD cases and 1,773 controls with 1,213 males and 2,298 
females. 
Genotyping data using the Perlegen 600K SNP chips (total 437,547 filtered SNPs) are 
available for 1,738 cases and 1,773 controls in the GAIN database. GWA genotyping for the 
selected candidates (see Chapter 3 for details) was done by Perlegen Sciences and the Stage 1 
results became available in 2007 via the National Center for Biotechnology Information (NCBI). 
The complete database of candidates’ phenotype and genotype information is known as dbGaP 
and it has the following web portal (http://www.ncbi.nlm.nih.gov).  Access to this public 
database requires preapproved applications for research in MDD with the restriction that use of 
the genotype and phenotype data is limited to psychiatric health and related somatic conditions. 
 
#2 OZALC Sample  
The data for the OZALC study were obtained from telephone diagnostic interviews of two 
general population volunteer cohorts consisting of Australian twins and their spouses, – a total of 
11,000 families. The data used come from the publicly available data from the Genome wide 
Association Study of Alcohol Use and Alcohol Use Disorder in Australian Twin-Families 
(OZALC GWAS) – Study Accession: phs000181.v1.p1. The details about these subjects are 
described elsewhere (Grant et al., 2009, Nelson et al., 2004). Genotyping data using the Illumina 
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Human CNV370v1 (total of 343,955 SNPs) are available for 4,119 individuals in this data set. 
After merging with pedigree and phenotype of Anti-Social Personality Disorder (ASPD), we 
removed one from each of 44 Monozygotic (MZ) twins and 72 outliers based on the data 
description. Consequently, 103 cases of ASPD were left. This database is used for replication 
study only and for finding common genetic variants in both Neuroticism and ASPD. This data 
set is used in the study of gene x gender interaction of neuroticism. 
 
Overview of Sample Selection, Data Collection, and Data Characteristics 
Sample Selection  
The defining features of MDD used for this study are those used for NESDA study and are 
marked by persistent depressive moods associated with physical and cognitive signs and 
symptoms (e.g., insomnia, anhedonia, appetite and weight changes, psychomotor agitation or 
retardation, etc.) as described in Boomsma et al. (2008). The combined dataset also contain 
severity indexes for mental disorders such as neuroticism and generalized anxiety disorder for 
MDD cases.  
Major Depressive Disorder Cases - Inclusions and Exclusions 
The inclusion criteria for the MDD cases were: 
 WMH-CIDI diagnosis of MDD 
 Age between 18-65 years 
 Knowledge of Dutch language 
 North-European ancestry. 
The exclusion criteria for the MDD cases were: 
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 People with primary diagnoses of psychosis, bipolar disorder, obsessive compulsion 
disorder, severe addiction disorder  
 Insufficient knowledge of the Dutch language 
Major Depressive Disorder Controls - Inclusions and Exclusions 
The inclusion criteria for MDD controls were: 
 Never scoring high (> 0.65) on a general factor score for anxious depression 
 Never reported any history of MDD 
 Age between 18-65 
 Knowledge of Dutch language 
 North-European ancestry 
The exclusion criteria for controls arose when there were multiple eligible controls in a 
family. In that case, gender and age were matched with cases first and then the control that 
completed the highest number of questions in the questionnaire was selected. 
The selected cases and controls in the GAIN database were then genotyped by Perlegen 
Sciences (Mountain View, CA) that was blinded as to the case or control status and the 
corresponding SNP data were stored in the database of Genotypes and Phenotypes (dbGaP) as a 
part of the GAIN initiative. 
Data  Collection  
The NESDA cases were selected from households in 90 Dutch municipalities and had been 
diagnosed with lifetime MDD or anxiety disorder during one of the CIDI interviews in 1996, 
1997, or 1999. The total catchment area for NESDA had a population of 1,175,000 people and 
selection was done using stratified random sampling to select potential study candidates and 
    
50 
 
7,076 people responded. The sample also included a subgroup of 18-25 year olds that 
participated in for the Adolescent at Risk for Anxiety and Depression.  
The collaborative NESDA study involved four academic and two nonacademic centers. 
NESDA was a longitudinal cohort study (1996 – 2004) that followed 2,850 persons, aged 18-65 
years, and had five assessments, one at the baseline and after 1, 2, 4, and 8 years of follow-up. 
The clinical diagnosis of MDD was based on a detailed survey. The criterion for a case selection 
was the diagnosis of a depressive or anxiety disorder during a standardized intake assessment. 
The process of recruitment consisted of three phases –  
1. A preliminary screening questionnaire filled out at the GP’s office where the subject 
consulted for depressive symptoms.  
2. Those who screened positive were phone interviewed with the short form of the CIDI.  
3. Those with current diagnosed MDD status were asked to participate in NESDA and 
were further invited for a baseline assessment that included the full WMH-CIDI 
interview.  
The final inclusion criterion was a diagnosis of DSM-IV MDD, an age between 18 and 65 
years and self-reported European ancestry (Boomsma et al., 2008). 
The controls data from the NTR were collected longitudinally by mail surveys every 2-3 
years since 1991. There are about 22,000 participants from 5,546 families who were all assessed 
for depressive symptoms, anxiety, neuroticism, and other personality disorders. The controls 
never scored high on a general factor score (mean = 0.0 and SD = 0.7; a score of > 0.65 
constitutes depressive disorder) to qualify for anxious depression. The factor score was a 
combined measure of neuroticism, depressive symptoms, and anxiety assessed via longitudinal 
questionnaires. These control subjects never reported a history of MDD in any survey or the 
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blood sampling visits. The controls were similar with cases in demographics (i.e., of Dutch 
origin), gender distribution (40% men and 60% women), and age (18-65). But they did not have 
a lifetime diagnosis of MDD or anxiety disorder as assessed by the WMH-CIDI. There were also 
a few (167) healthy controls selected from NESDA study in this sample. Further details of 
selection objectives, recruitment, and methods of NESDA have been described elsewhere 
(Boomsma et al., 2008; Kessler, et al. 2003; Penninx, et al., 2008). 
Data  Characteristics  
Baseline characteristics of cases and controls are summarized in Tables 1 and 2 given on the 
website (www.ncbi.nlm.nih.gov/dbgap) on October 9, 2007. Accordingly, the ages of 
participants (both cases and controls) were not significantly different, but the number of women 
in cases was higher than in controls. More controls were married or living with a partner (20% 
more) than cases and there were almost double the number of cases who smoked (42% vs 20%) 
compared to controls. Alcohol use was higher in controls than in cases (80% vs. 66%) and the 
NEO neuroticism score had a higher mean in cases than in controls (39.3 vs. 28.2). More 
complete details of how the data were collected, sampled, and the establishment of the Genetic 
Association Information Network (GAIN) are described by Boomsma (Boomsma et al., 2008).  
 
Table 1  
Characteristics of GAIN MDD Cases 
Characteristic Predictor Type MDD Cases; N = 1821 
Age (years) Continuous 42.1 ± 12.7 
Female (% Yes) Categorical 69.7 
With Partner / Married (% Yes) Categorical 68.5 
Smoking (current in % Yes) Categorical 42.1 
Alcohol use (last year in % Yes) Categorical 66.3 
NEO
a
 neuroticism score (0 – 60) Continuous 39.3 ± 8.0 
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Table 1 (Continued) 
Family history of MDD (% Yes) Categorical 85.4 
Depression; Age at Onset (years) Continuous 27.5 ± 12.3 
IDS
b
 depression (0 – 69) Continuous 25.8 ± 13.5 
BAI
c
 anxiety (0 -62) Continuous 14.3 ± 10.6 
For continuous traits, the mean score and SD are listed. 
a
NEO = Neuroticism, Extrovertness, Openness. 
b
IDS = Index of Depressive Symptomatology. 
cBAI = Beck’s Anxiety Inventory.  
 
Table 2 
Characteristics of GAIN MDD Controls 
Characteristic Predictor Type MDD Controls; N = 1822 
Age (years) Continuous 45.1 ± 14.1 
Female (% Yes) Categorical 61.8 
With Partner / Married (% Yes) Categorical 87.0 
Smoking (current in % Yes) Categorical 20.4 
Alcohol use (last year in % Yes) Categorical 80.0 
NEO
a
 neuroticism score (0 - 60) Continuous 28.2 ± 5.5 
ABV
b
 neuroticism score (11 -124) Continuous 36.7 ± 16.0 
ABV somatic complaints (12 – 46) Continuous 15.9 ± 3.8 
STAI
c
 trait anxiety (20 – 79) Continuous 30.1 ± 5.6 
YASR
d
 anxious depression (0 – 21) Continuous 3.22 ± 2.7 
Beck depression (0 – 23) Continuous 1.11 ± 1.4 
For continuous traits, the mean score and SD are listed. 
a
NEO = Neuroticism, Extrovertness, Openness. 
b
ABV = Amsterdam Biographic Survey. 
c
STAI = Spielberger Trait Anxiety Inventory. 
d
YASR = Young Adult Self Report.  
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Formation of dbGaP  
From the NESDA participants the cases for the GAIN MDD study and genotyping were 
selected from September 2004 through February 2007. Although an initial 1,821 cases and 1,822 
controls were available for analyses, final selection in the GAIN sample excluded certain 
subjects (because of genotyping and sample problems) and included some others (e.g., parents of 
some controls) to form trios (the subject and his/her parents). After the above adjustments a total 
of 1,860 cases and 1,857 controls were included in the GAIN database.  
Figure 1 below illustrates the make-up of the GAIN database of genotypes and phenotypes 
(dbGaP). The phenotype data for NESDA consisted of responses from the WMH-CIDI forms 
(described in Appendix A2) and represented MDD, depressive symptoms, and other 
psychopathology indicators. In addition, the CIDI interview also provided information on age at 
onset, number of episodes of MDD, and specific symptoms of depression along with quantitative 
scores for NEO-FFI, IDS and BAI. 
The biobank samples from NESDA and NTR participants were collected and stored at the 
time of their baseline visit for CIDI interviews (for NESDA participants) and a separate blood or 
urine collection project (for NTR participants). All necessary protocols were followed for 
collection, storage, and genotyping of the biosamples. The dbGaP holds both phenotype and 
genotype information for cases and controls. The individual researcher or the team of researchers 
who gets access to the data in dbGaP might be required to reformat the data tables to suit the 
needs of a particular study.  
For example, a data item in a specific column of a table in the database might not be useful 
for a specific study and may have to be deleted; or, one may want to categorize a continuous data 
item (e.g., age of 18-65 may be categorized into 18-30, 31-60, 61+), etc. In case of genotypes 
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data one may have to filter the data for conformity with Hardy-Weinberg proportion and 
Minimum Allele Frequency (usually > 1%) and so one might eliminate certain SNPs and 
individual data row. 
 
Figure 1. Formation of dbGaP 
 
In addition, one may want to eliminate outliers in the data and so might need to use other 
software tools to run the data required first before making it ready for the required analyses. This 
type of preliminary processing for needed quality control of the data is the responsibility of the 
researcher who is given access to the dbGaP data. 
NESDA  NTR 
 
Perlegen Genotyping 
Services 
 
Quality 
Control 
Biosamples 
dbGaP 
Cases’ 
Biosamples 
Cases’ 
Phenotypes 
Cases + Controls 
Genotypes 
Controls’ 
Phenotypes 
Controls’ 
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 Formation of dbGaP Database 
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Study Designs for Data Analyses 
Using the two data sets described above, three study designs are developed below for 
addressing the three research questions we identified earlier in chapter 1. These are given below: 
Study Design for Research Goal #1: Risk Factors for Major Depressive Disorder 
Only the primary data set #1 GAIN dbGaP described earlier was used to address this research 
goal.  
Study population. Data from 3,356 individual records sampled from the NESDA/NTR 
phenotypes dataset and stored in GAIN dbGaP was used to conduct descriptive and regression 
analyses.  
Study Variables. Four continuous and five categorical predictor variables are used in order to 
determine the various quantitative relationships. These are shown in Table 3. 
Table 3  
Study Variables Used for Research Goal #1 
Outcome Variable Predictor Variables 
MDD Affection Status (Binary) Age (continuous) 
 Gender (categorical) 
 Marital status (categorical) 
 Smoking Status (categorical) 
 Alcohol Use (categorical) 
 Family Risk (categorical) 
 Neuroticism (NEO) (continuous) 
 
Index of Depressive Symptomatology (IDS) 
(continuous) 
 Beck’s Anxiety Index (BAI) (continuous) 
Neuroticism (Continuous) Age (continuous) 
 Gender (categorical) 
 Marital status (categorical) 
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Table 3 (Continued)  
 Smoking Status (categorical) 
 Alcohol Use (categorical) 
 Family Risk (categorical) 
 
Index of Depressive Symptomatology (IDS) 
(continuous) 
 Beck’s Anxiety Index (BAI) (continuous) 
Age at Onset (Continuous) Gender (categorical) 
 Marital status (categorical) 
 Smoking Status (categorical) 
 Alcohol Use (categorical) 
 Family Risk (categorical) 
 
Index of Depressive Symptomatology (IDS) 
(continuous) 
 Beck’s Anxiety Index (BAI) (continuous) 
 Neuroticism (NEO) (continuous) 
 
The potential confounders are Age, Gender, Marital Status, Smoking Status, Alcohol Use, 
and Family Risk. The potential effect modifiers are Gender, Smoking Status, and Family Risk.  
Statistical Methods 
Descriptive Analyses. SAS 9.2 and SPSS 17 were used for descriptive analyses. Univariate 
analysis was conducted to obtain baseline information prior to conducting more advanced 
bivariate and multiple variable analyses. The univariate analysis of MDD phenotypes such as 
NEO, IDS, and BAI provide us an estimate of distributions of phenotypes in the study 
population. Histograms and box plots were used to graphically show and compare the prevalence 
of specific MDD phenotypes for men and women, married and unmarried, smokers and 
nonsmokers, and so forth. We hope to replicate prior established facts such as a higher 
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prevalence of MDD in females as opposed to males, comorbidity smoking and MDD, and 
described familial risks for MDD such as an affected first-degree relative increasing the risk of 
MDD in individuals. In addition, the statistical distributions of continuous and categorical 
predictors are plotted using SPSS software. 
Bivariate Analyses. Simple logistic regression methods were used to analyze the data in order 
to evaluate the association of the covariates and MDD. Bivariate logistic regressions of the 
primary outcome variable (MDD affection) were carried out for age, neuroticism score, gender, 
marital status, smoking status, alcohol use, and family risk. The results were used to examine the 
strength of the potential risk association of the different predictors for MDD and its related 
phenotypes.  
Multiple Variable Analyses. Multiple logistic regressions were used to measure the 
relationship between the outcome variable MDD affection and the different predictors of interest. 
Multiple logistic regressions use an odds ratio (OR) to assess the association and potential risk of 
MDD affection for one predictor while adjusting for all other predictors or covariates. The 
covariates that were used for multiple logistic regression of MDD affection are – age, gender, 
marital status, smoking status, alcohol use, neuroticism score, and family risk. Multiple linear 
regressions of continuous predictors like NEO, IDS, and BAI assess the relationship between the 
continuous outcome variable (NEO, IDS, BAI) and a predictor like age, gender, marital status, 
smoking status, etc. while adjusting for all other covariates.  
The SAS procedures used for analyses are “proc reg”, “proc logistic”, and Generalized 
Linear Model (“proc glm”). Odds ratios along with Wald confidence intervals for MDD with 
predictor variables are computed using the multiple logistic regression procedure. The multiple 
regression procedures used ‘backward’ selection of variables and included only those predictors 
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that were significant at the level of 0.05 alpha values. In addition, interactions were tested for the 
three leading predictor variables - gender, smoking status, and family risk. The “glm” procedure 
is used with the predictors gender, marital status, smoking status, alcohol use, and family risk - 
as class variables to discover potential confounding effects. After eliminating the confounding 
effects of predictors using multiple variable regressions a reasonable relationship between the 
primary outcome variable (MDD affection) and the predictor variables (MDD phenotypes) were 
assessed. 
Study Design for Research Goal #2: Genome-Wide Association Analysis of Neuroticism 
Two data sets are used in this study – one primary (#1 GAIN dbGaP) and one secondary (#2 
OZALC) for replication purposes. The data sets #1 and #2 were described earlier in the sections 
on data sources and participants.  
Study Population. For this Research Goal, 2,748 individuals (902 males and 1,846 females) 
were analyzed. There were 437,547 SNPs available for the data. These managed data were the 
result of the data quality control and stratification steps taken in the previous phase. Any 
additional data management required before analyzing the continuous severity variables selected 
using PLINK and/or other software was accomplished first. The second data set is used for 
comparing the results of significant SNPs obtained in the association studies with the significant 
SNPs obtained from a family-based association analysis of Australian twins for Anti-Social 
Personality Disorder (Wang et al., 2011). 
Study Variables. Both phenotypic and genotypic variables were used in this study. The 
outcome variable Neuroticism (NEO) and the predictor Age were continuous variables and the 
covariates Gender and Genotype were categorical. The genotypes of 902 males and 1,846 
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females available from the study data set #1 were used for both neuroticism association and gene 
x gender interaction studies. 
Statistical Methods. 
Quality Control. For the initial GWA analysis of MDD, HelixTree Software 
(http://www.goldenhelix.com/SNP_Variation/HelixTree/index.html) was used to assess genotype 
data for conformity with Hardy-Weinberg equilibrium (HWE). To deal with population 
stratification, the principal-component analysis approach (Price et al., 2006) in HelixTree was 
used to identify outlier individuals.  
Linear Model. To test for association with a quantitative trait, linear regression was 
performed by PLINK to obtain the regression coefficient and Wald test asymptotic p-value. In 
addition to obtaining nominal P-values, empirical P-values are generated by 100,000 permutation 
tests using Max (T) permutation procedure implemented in PLINK. In this procedure, the 
corrected values for multiple testing (corrected empirical P-values) are calculated. 
1. Gender-specific association study with separate male and female samples 
(a) QT = b0 + b1*ADD + b2*Gender + b3*Age + e 
where, QT is a quantitative trait (neuroticism), ADD is a dummy variable for coding the 
possible genotypes AA, Aa, and aa with the additive model; Gender is the variable for coding 
male or female sample data in the additive model; b0 is the intercept, b1, b2, b3 are the 
corresponding regression coefficients, and e is the error term. 
For neuroticism, we used (a) to perform association analysis for MDD case samples controlling 
age. 
2. Gene x gender interactions of neuroticism 
 (b) QT = b0 + b1*ADD + b2*Gender + b3*ADDxGender + b4*Age + e 
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where, QT is the quantitative trait (Neuroticism) being analyzed, ADD is the dummy variable 
for coding three genotypes AA, Aa, and aa with additive model, b0, b1, b2, b3, and b4 are the 
corresponding intercept, individual regression coefficients, Age and Gender are the covariates 
being used and e is the error term.  
For neuroticism, we used (b) to test gene x gender interactions controlling age. 
Statistical Significance. We used a conservative per test significance level of α=5x10-7 
(Wellcome Trust Case Control Consortium, 2007). At the same time, we also had a less stringent 
criterion of “suggestive association” with a cut-off of α=10-4.  
Study Design for Research Goal #3: Genome-Wide Association Analysis of Age at Onset 
Only the primary data set #1 GAIN dbGaP as described earlier was used for this analysis.  
Study Population. Sixteen hundred three subjects (481 males and 1,122 females) were used 
for this analysis. There were 437,547 SNPs available for the data. This managed data were the 
result of the data quality control and stratification steps taken in the previous phase. Any 
additional data management required before analyzing the continuous severity variables selected 
using PLINK and/or other software were accomplished first. 
Study Variables. Both phenotypic and genotypic variables were used in this study. The 
outcome variable Age at Onset (AAO) was a continuous variable and the covariates Gender and 
Genotype were categorical. The genotypes of 481 males and 1,122 females available from the 
study data set #1 were used for AAO association with MDD. 
Statistical Methods 
Linear Model. Linear model analysis was performed for AAO using PLINK v1.07 (Purcell et 
al., 2007). To test for association with AAO as a quantitative trait, linear regression was 
performed by PLINK to obtain the regression coefficient and Wald test asymptotic p-value. 
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(a) QT = b0 + b1*ADD + b2*Gender + e 
where, QT is a quantitative trait (Age at Onset), ADD is a dummy variable for coding the 
possible genotypes AA, Aa, and aa with the additive model; Gender was the variable for 
coding male or female sample data in the additive model; b0 is the intercept, b1 and b2 are 
the corresponding regression coefficients, and e is the error term. 
For Age at Onset we used (a) to perform association analysis for MDD case samples 
controlling gender. 
Statistical significance. We used a conservative per test significance level of α=5x10-7 
(Wellcome Trust Case Control Consortium, 2007). At the same time, we also had a less 
stringent criterion of “suggestive association” with a cut-off of α=10-4.  
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CHAPTER 4 
RESULTS 
The results from the three studies identified in the previous chapter are presented here. First, 
some of the results from the descriptive analyses are illustrated as graphical plots showing some 
of the significant distributions of MDD related phenotypes in the sample population selected for 
univariate analyses. The histograms illustrated below in Figure 2 correspond to two of the three 
major predictors of MDD we have found, namely, gender and marital status. Because smoking is 
both a confounder and a possible effect modifier, and because we do not know whether the 
smoking data are pre- or postdiagnosis of MDD, we cannot rely on any illustrative 
interpretations of the raw distribution plots that involve any smoking data.  
 
Figure 2. Comparison of Mean Neuroticism Scores 
Comparison of Mean Neuroticism Total Score in 
a Sample from the Netherlands Study of MDD 
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The histograms show the pattern of mean frequencies in our NESDA-based sample and 
should not be generalized for any other population. From Figure 2 we can surmise that the mean 
score for NEO-FFI in unmarried females seems to be slightly higher (in value) than unmarried 
males but certainly higher than both married males and females. 
In Figure 3 we see that the age at onset is the earliest in unmarried males while not much 
difference is seen in case of females. The finding that unmarried males are prone to early age at 
onset of MDD will need to be further evaluated by future studies. 
In Appendix C we show some other histograms generated during the descriptive analysis and 
Gene x Gender interaction analysis of Neuroticism scores in our sample. 
 
Figure 3. Comparison of Mean Age at Onset 
 
Comparison of Mean Age at Onset of MDD in a 
Sample from the Netherlands Study of MDD 
Figure 3: Comparison of Mean Neuroticism Scores 
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Risk Factors of Major Depressive Disorder 
The results from the logistic regression of Affection_Status of MDD for each of the predictor 
variables – Age, Gender, Marital Status, Smoking Status, Alcohol Use, Family Risk and NEO 
Score are summarized in Table 4 below. They all show statistically significant relationships with 
MDD.  The OR estimates indicate that Age, Marital Status, and Alcohol Use show a reduction in 
risk OR < 1); all others show increased risks (OR > 1). The bivariate analyses do not adjust for 
potential confounding and further evaluations are required. Table 4 shows the following odds 
ratios and confidence intervals for each of the predictors tested – Age (OR: 0.984, 95%CI: 0.980 
– 0.989); Gender (OR: 1.428, 95% CI: 1.242 – 1.643); Marital Status (OR: 0.327, 95% CI: 0.275 
– 0.389); Smoking Status (OR: 2.879, 95% CI: 2.476 – 3.347); Alcohol Use (OR: 0.498, 95% 
CI: 0.426 – 0.583); Family Risk (OR: 3.451, 95% CI: 2.423 – 4.916); NEO Score (OR: 1.243, 
95% CI: 1.223 – 1.264). 
Table 4 shows the bivariate analyses for Family Risk and NEO Score with reduced sample 
sizes. The sample sizes for these analyses are reduced because the phenotypes evaluated apply 
only to cases and some of the data (esp. for family risk) are missing in the dataset #1. Further 
discussion of these results is deferred until Chapter 5. 
Table 4  
Bivariate Logistic Regression of Major Depressive Disorder with Predictor Variables 
Outcome Variable = Affection_Status (MDD) 
Predictor 
Variable 
N 
Model Fit   
(-2LL) 
Parameter 
Estimate 
Wald χ2 p-value OR 
95% CI for 
OR  
Age 3,510 4,827.322 -0.0156 37.8419 < 0.0001 0.984 
(0.980 – 
0.989) 
Gender 3,511 4,841.868 0.3564 24.9257 < 0.0001 1.428 
(1.242 – 
1.643) 
Marital Status 3,457 4,620.548 -1.1183 158.9867 < 0.0001 0.327 
(0.275 – 
0.389) 
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Table 4 (Continued) 
Smoking 
Status 
3,488 4,636.111 1.0574 189.4331 < 0.0001 2.879 
(2.476 – 
3.347) 
Alcohol Use 3,380 4,606.269 -0.6965 75.7377 < 0.0001 0.498 
(0.426 – 
0.583) 
Family Risk 1,826 1,018.826 1.2387 47.0730 < 0.0001 3.451 
(2.423 – 
4.916) 
NEO Score 2,748 2,529.105 0.2176 666.5801 <0.0001 1.243 
(1.223 – 
1.264) 
 
Multiple variable regressions with adjustment for confounding must be carried out before 
specific predictors might be held responsible for possible associations with the outcome of 
diagnosed MDD affection in a subject from the study sample. Multiple variable logistic 
regressions were run with the binary outcome variable (i.e., Affection_Status) for MDD and the 
requisite predictors identified earlier – Age, Gender, Marital Status, Smoking Status, Alcohol 
Use, and Family Risk. The SAS regression tool eliminated the predictor ‘Age’ from 
consideration because of statistical insignificance (P-value > 0.05) and other reasons. We used 
age as a continuous variable and did not categorize the age into different categories that could 
have shown significance in certain age groups (e.g. postadolescence age of 17-25). The analysis 
was carried out starting with the predictor family risk first;  other predictors were added one at a 
time in the following order – NEO Score, Smoking Status, Alcohol Use, Marital Status, and 
Gender. The results of logistic multiple variable regressions of Affection_Status (for MDD) with 
individual predictor variables are shown in Table 5 below. Tables 6, 7, and 8 show results from 
the interaction studies of the significant predictors. 
Table 5 shows the following odds ratios and confidence intervals for each of the predictors 
tested – Gender-female (OR: 1.282, 95% CI: 1.078 – 1.602); Marital Status (OR: 0.432, 95% CI: 
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0.330 – 0.564); Smoking Status (OR: 3.079, 95% CI: 2.447 – 3.874); Alcohol Use (OR: 0.407, 
95% CI: 0.318 – 0.521); Family Risk (OR: 3.112, 95% CI: 2.172 – 4.461); NEO Score (OR: 
1.231, 95% CI: 1.210 – 1.253). The predictor Age is not at all significant (p = 0.7496) and was 
eliminated in the analysis as a predictor by the SAS program. The corresponding results for Age 
are shown as greyed out in Table 5. 
Our analyses demonstrate that the major risk factors for MDD are Gender, Smoking Status, 
Family Risk, and NEO Score. The odds ratios (ORs) for Gender (female), Smoking Status, 
Family Risk, and NEO Score all show increased risks for MDD. The adjustment for confounding 
does not remove the higher risk of MDD that was noted for female Gender, Smoking Status and 
the Family Risk (i.e., a history of depression among the first degree relatives. The interaction 
between Gender and Smoking Status, Gender and Family Risk, and Smoking Status and Family 
Risk do not show any significance at a 5% (alpha = 0.05) significance level. Further discussion 
of these results is given in Chapter 5. 
 
Table 5  
Multiple Logistic Regression of Major Depressive Disorder with Predictor Variables  
Outcome Variable = Affection_Status (MDD); 
N = 2730;  -2LogL = 2330.167; Wald χ2 =696.0755;  p < 0.0000000001 
Predictor 
Variable 
Parameter 
Estimate 
Wald χ2 p-value OR 95% CI for OR  
Age -0.0013 0.1021 0.7493 0.999 (0.991 – 1.006) 
 Gender +1.2488 4.8161 0.0282 1.282 (1.078 – 1.602) 
Marital Status -0.8403 38.0185 0.0000000007 0.432 (0.330 – 0.564) 
Smoking Status +1.1245 23.7250 < 0.0000000001 3.079 (2.447 – 3.874) 
Family Risk +1.1354 38.2266 < 0.0000000001 3.112 (2.172 – 4.461) 
Alcohol Use -0.8980 50.9876 < 0.0000000001 0.407 (0.318 – 0.521) 
NEO Score +0.2082 565.9205 < 0.0000000001 1.231 (1.210 – 1.253) 
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Table 6  
Multiple Logistic Regression of Major Depressive Disorder with Interaction Terms Gender*Smoking Status 
Outcome Variable = Affection_Status (MDD); 
N = 3488;  Hosmer & Lemeshow Model Fit χ2 = 0.0000;  p = 1.0000 
Predictor 
Variable 
Parameter 
Estimate 
Wald χ2 p-value OR 95% CI for OR  
 Gender 0.3495 15.3997 < 0.0001 1.501 (1.298 – 1.735) 
Smoking Status 0.9678 59.1310 < 0.0001 2.966 (2.546 – 3.454) 
Gender*Smoking 
Status 
0.1818 1.2941 0.2553 n/a n/a 
  
Table 7  
Multiple Logistic Regression of Major Depressive Disorder with Interaction Terms Gender*Family Risk 
Outcome Variable = Affection_Status (MDD); 
N = 1826;  Hosmer & Lemeshow Model Fit χ2 = 0.0000;  p = 1.0000 
Predictor 
Variable 
Parameter 
Estimate 
Wald χ2 p-value OR 95% CI for OR  
 Gender 0.3946 1.7784 0.1823 1.351 (0.933 – 1.958) 
Family Risk 1.2680 20.8312 < 0.0001 3.293 (2.283 – 4.749) 
Gender*Family 
Risk 
-0.1117 0.0922 0.7614 n/a n/a 
 
Table 8 
Multiple Logistic Regression of Major Depressive Disorder with Interaction Terms Smoking Status*Family Risk 
Outcome Variable = Affection_Status (MDD); 
N = 1825;  Hosmer & Lemeshow Model Fit χ2 = 0.0000;  p = 1.0000 
Predictor 
Variable 
Parameter 
Estimate 
Wald χ2 p-value OR 95% CI for OR  
 Smoking Status 1.2949 10.2781 0.0013 2.555 (1.686 – 3.872) 
Family Risk 1.2646 38.1491 < 0.0001 2.970 (1.964 – 4.491) 
Smoking 
Status*Family 
Risk 
-0.4264 0.8222 0.3645 n/a n/a 
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Notice that the results for OR and 95% CI’s have been greyed out in tables 8, 9, and 10 
above because the interaction terms are not significant at the p < 0.05 level and thus the 
corresponding values of ORs and 95% CIs need to be recomputed. 
 
Genome-Wide Association Analysis of Neuroticism 
First we tested the association of neuroticism as a quantitative trait in PLINK to obtain the 
Wald test asymptotic p-value. Thirty-four significant (p < 10
-4
) neuroticism (as a quantitative 
trait) associated SNPs were detected in this analysis. Table 9 shows the top 20 neuroticism 
associated SNPs along with any associated genes and/or flanking marker genes. Accordingly, the 
best SNP associated with neuroticism (p < 10
-5
) was rs4806846 (p = 7.79x10
-6
) within 
TMPRSS9 gene and the next best was rs220549 (p = 1.05x10
-5
) in GRIN2B gene. The SNP 
rs1046329 (p = 1.37x10
-5
) in the gene SGCA is the third best. In addition, Table D-1 (Appendix 
D) shows the complete list of asymptotic P-values for the 34 significant SNPs (p < 10
-4
) along 
with the corresponding P-values in the separated male and female populations. 
In Table 9 it is interesting to notice the widely differing p-values for males and females for 
some significant (p < 10
-4
) SNPs. For example, for the SNP rs1046329 the female p-value is 
2.88x10
-5
 whereas the same SNP is insignificant in males with p = 0.1835. Similarly, the SNP 
rs4342432 is significant (p < 10
-3
) in females (p = 0.0001645) but not in males (p = 0.1475).  
Table 9 
Genome-Wide Association Study Results of Significant SNPs for Neuroticism in Major Depressive 
Disorder 
*
 
CHR 
Reference 
SNP 
Position
a 
Gene Name
 
Gene 
Location
 
P-value 
Total
b 
P-value 
Male
c 
P-value 
Female
d 
19 rs4806846 2361484 TMPRSS9 19p13.3 7.79E-06 0.001109 0.002405 
12 rs220549 13828587 GRIN2B 12p12 1.05E-05 0.05337 0.0002437 
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Table 9 (Continued) 
17 rs1046329 45603905 SGCA  17q21  1.37E-05 0.1835 2.88E-05 
2 rs6757820 147996163 ACVR2A  2q22.3 1.51E-05 0.003489 0.002758 
6 rs4510687 96219582 
 (MANEA & 
FUT9) 
6q16.1  2.49E-05 0.1229 0.0001593 
3 rs985280 64083893 PSMD6 3p14.1 2.61E-05 0.07875 0.0009192 
6 rs4342432 96195874     2.96E-05 0.1475 0.0001645 
16 rs9807002 26184920     3.05E-05 0.1409 0.000289 
14 rs9323020 21228477 
Near 
EDDM3B 
14q11.2 3.29E-05 0.06499 0.0001355 
17 rs8068962 9254866 STX8 17p12 3.32E-05 0.05502 0.001416 
2 rs2344734 152400075 NEB 2q22 3.61E-05 0.1872 0.0005467 
2 rs12620464 101396078     4.09E-05 0.04817 0.0006929 
8 rs1608361 123732642 
LOC1001315
52 
8q24.13 4.13E-05 0.08719 0.004728 
2 rs10930046 162846229     4.68E-05 0.06334 0.001034 
5 rs6894463 3266546     4.81E-05 0.001539 0.003872 
17 rs2301685 32452234     4.94E-05 0.1001 0.002558 
20 rs6065392 39870080 ZHX3 20q12 5.02E-05 0.06333 0.001298 
11 rs10835855 32165526     5.15E-05 0.06333 0.001298 
8 rs16915079 51685259 
Near 
CYCSP22 
8q11.22 5.54E-05 0.03473 0.006221 
3 rs9834457 69604258 
Near 
LOC642487 
3p14.1 6.10E-05 0.02482 0.000309 
*
 CHR = Chromosome Number; SNP = Single Nucleotide Polymorphism 
a
 Physical position is based on NCBI genome build 36.3. 
b
 Wald test asymptotic P-value for the association of neuroticism with MDD in the total sample. 
c
 Wald test asymptotic P-value for the association of neuroticism with MDD in the male sample. 
d
 Wald test asymptotic P-value for the association of neuroticism with MDD in the female sample. 
 
In addition, those significant SNPs (p < 10
-1
) that are significant for ASPD in the OZALC 
study that share the same genomic regions as the significant (p < 10
-1
) neuroticism SNPs are 
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shown in Table 10. Accordingly, 8 SNPs in the region of the significant gene markers (GRIN2B, 
OR10G2, OR4E2, and RNASE1 on chromosomes 12 and 14) for association of neuroticism in 
the NESDA sample were found with borderline associations for ASPD in the Australian sample 
at a P-value of 0.09 or lower. Table D-4 shows the complete list of ASPD P-values for SNPs in 
the region of implicated genes for neuroticism. 
Table 10 
Genome-Wide Association Study Results of Significant SNPs for ASPD in the Region of Implicated 
Genes for Neuroticism
*
 
CHR 
Reference 
SNP 
Gene 
Name 
P-
Neoneu 
Total
a 
P-
Neoneu 
Male
b 
P-
Neoneu 
Female
c 
P-
MDD-
Total
d 
P-
MDD-
Male
e 
P-
MDD-
Female
f 
OZ-
ASPD 
Sample 
P-value
g 
12 rs11055608 GRIN2B 0.9412 0.8302 0.5511 0.7588 0.3476 0.2884 0.06706 
12 rs2216127 GRIN2B 0.08245 0.4308 0.07982 0.0391 0.1045 0.1781 0.04839 
12 rs7974275 GRIN2B 0.865 0.9641 0.4977 0.4612 0.7569 0.2365 0.01938 
14 rs10146821 OR10G2 0.08711 0.07005 0.7192 0.5681 0.3188 0.8758 0.04173 
14 rs2874103 OR4E2 0.1635 0.8785 0.05961 0.2232 0.3295 0.3568 0.08020 
14 rs970382 OR4E2 0.1826 0.8555 0.06383 0.2245 0.3046 0.3741 0.09011 
14 rs718433 
Near 
RNASE1 
0.7877 0.643 0.5419 0.8413 0.7324 0.5755 0.05733 
14 rs2141971 
Near 
RNASE1 
0.7169 0.2254 0.3192 0.3974 0.7782 0.1487 0.00448 
 
*
 CHR = Chromosome Number; SNP = Single Nucleotide Polymorphism; MDD = Major Depressive 
Disorder; ASPD = Anti-Social Personality Disorder. 
a, b, c
 Wald test asymptotic P-value for the association of neuroticism with MDD in the total, male, and 
female sample. 
d, e, f
 Wald test asymptotic P-value for the association with MDD in the total,  male, and female sample. 
g
 Wald test asymptotic P-value for the association with ASPD in the OZALC sample. 
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Finally, Table 11 shows the top 20 significant (p < 10
-4
) gene x gender interaction SNPs for 
neuroticism along with the corresponding Wald asymptotic P-values in the total, male-only and 
female-only population in our sample discussed in Chapter 3. Table D-2 gives the complete list 
of significant (p < 10
-4
) SNPs. Top three significant (p < 10
-5
) SNPs are rs243012 (p = 5.37x10
-6
) 
in the gene HMCN1, rs17674783 (p = 6.92x10
-6
) in the gene SNTG1 and rs2612437 (p = 
9.30x10
-6
) in the intergenic region between the genes MAP2K4 and MYOCD. These findings are 
further elaborated in Chapter 5 in terms of any gene functionality and possibly other disease 
associations available from the literature. 
Table 11 
Genome-Wide Association Study Results of Significant SNPs for Gene x Gender Interaction of 
Neuroticism
*
 
CHR 
Reference 
SNP 
Gene Name 
Gene 
Location 
P-assoc 
Total
a 
P-assoc 
Male
b 
P-assoc 
Female
c P_GxE 
1 rs2430132 HMCN1 
1q25.3-
q31.1 
0.351 0.4283 0.6643 5.37E-06 
8 rs17674783 SNTG1 8q11-q12 0.8544 0.5047 0.999 6.92E-06 
17 rs2612437 
(MAP2K4 & 
MYOCD)  
0.9471 0.526 0.5177 9.30E-06 
12 rs11614157 (PRP1R12A & 
C12orf64)   
0.0612 0.3835 0.2374 1.48E-05 
4 rs244052 ENPEP 4q25 0.2467 0.9248 0.4139 1.53E-05 
8 rs391798 SNTG1 8q11-q12 0.9659 0.483 0.8758 1.53E-05 
4 rs13146994 ATP8A1 4p14-p12 0.3128 0.2118 0.4046 1.66E-05 
20 rs6072394     0.2119 0.9787 0.3763 1.77E-05 
3 rs9834626 RPL10AP6  3p14.2 0.6774 0.454 0.5157 1.78E-05 
15 rs870335 SMAD3 15q22.33 0.9354 0.4891 0.411 2.28E-05 
20 rs2326424 ADRA1D  20p13 0.04644 0.01311 0.2266 2.69E-05 
14 rs17111534 LOC100288480  14q11.2 0.3991 0.9245 0.1688 2.78E-05 
2 rs12692083 ISCA1P6  2q14.3 0.7659 0.2809 0.09403 2.83E-05 
15 rs2415037 SMAD3 15q22.33 0.8592 0.5387 0.4015 3.00E-05 
15 rs1532758 SMAD3 15q22.33 0.2269 0.973 0.07676 3.50E-05 
8 rs1023979     0.2049 0.377 0.5902 3.65E-05 
6 rs11970411 TNFA1P3 6q23 0.9345 0.8628 0.8696 3.66E-05 
5 rs6595727     0.1771 0.02356 0.9237 3.68E-05 
8 rs4412393     0.6117 0.06589 0.3106 3.75E-05 
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Table 11 (Continued) 
8 rs7832224 EFR3A 8q24.22 0.2561 0.8041 0.2023 4.21E-05 
 
*
 CHR = Chromosome Number; SNP = Single Nucleotide Polymorphism; MDD = Major Depressive 
Disorder; 
a, b, c
 Wald test asymptotic P-value for the association of neuroticism with MDD in the total, male, and 
female sample. 
 
Genome-Wide Association Analysis of Age at Onset of Major Depressive Disorder  
The top 20 significant (p < 10
-4
) SNPs associated with age at onset in MDD cases are 
tabulated below in Table 12. The highlighted portions in the table show SNPs that are significant 
at the genome-wide level (i.e., p-value < 5x10
-7
). These are – rs734253 in the gene GPR143 (p = 
2.54x10
-12
), rs6641545 in the gene ASS1P4 (p = 9.75x10
-10
), rs5983118 in the gene MXRA5 (p 
= 5.67x10
-8
) and rs6654462 flanked by the genes MAGEC1 and MAGEC2 (p = 3.99x10
-7
). In 
addition we have found three more highly significant (p < 10
-5
) SNPs at the 10
-6
 level which are 
– rs32589 (p = 4.72x10-6), rs9294523 (p = 5.83x10-6), and rs10515638 (p = 9.77x10-6). The 
complete list of associated (p < 10
-4
) SNPs for age at onset association is shown in Table D-5 in 
Appendix D. In chapter 5, we elaborate more on the implicated genes for age at onset in terms of 
any known functionality, association with other known diseases in both animal and human 
models. 
Table 12 
Genome-Wide Association Study Results of Significant SNPs for Age at Onset of MDD
* 
CHR 
Reference 
SNP 
Gene Name 
Gene 
Location 
P-
MDD-
Total
a 
P-
MDD-
Male
b 
P-
MDD-
Female
c 
P-
Neuroticism
d P-AAO
e 
23 rs734253 GPR143 Xp22.3 0.3747 N/A 0.8116 0.2357 
2.54E-
12 
23 rs6641545 ASS1P4 Xp22.33 0.7671 0.2733 0.2551 0.64 
9.75E-
10 
23 rs5983118 MXRA5 Xp22.33 0.398 N/A 0.1451 0.5025 
5.67E-
08 
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Table 12 (Continued) 
23 rs6654462 
Flanked by 
MAGEC1 and 
MAGEC2 
Xp26-
Xp27 
0.3369 0.7451 0.1007 0.1432 
3.99E-
07 
5 rs32589 PPARGC1B 5q32 0.7074 0.0051 0.0168 0.5262 
4.72E-
06 
6 rs9294523 RPL5P19 6q15 0.5052 0.0952 0.0459 0.6942 
5.83E-
06 
5 rs10515638 PPARGC1B 5q32 0.8893 0.0133 0.1193 0.2302 
9.77E-
06 
5 rs26125 PPARGC1B 5q32 0.494 0.0068 0.0066 0.5332 
1.04E-
05 
23 rs5939057 ZCCHC16 Xq23 0.284 0.5247 0.1672 0.6689 
1.34E-
05 
5 rs17110375 PPARGC1B 5q32 0.62 0.0716 0.0686 0.0779 
1.42E-
05 
6 rs6570806 N/A N/A 0.1601 0.0838 0.0129 0.8842 
3.23E-
05 
8 rs16938568 RDH10 8q21.11 0.6015 0.1612 0.9382 0.1362 
3.36E-
05 
12 rs11107320 
LOC10013212
6 
12q22 0.4294 0.2577 0.1283 0.1142 
3.41E-
05 
11 rs3016415 GRIK4 11q22.3 0.6102 0.0176 0.0251 0.8042 
3.50E-
05 
6 rs10947795 KCNK16 
6p21.2-
p21.1 
0.5245 0.0112 0.4695 0.2657 
3.71E-
05 
22 rs34074034 TTLL12 
22q13.3
1 
0.2529 0.0134 0.9774 0.4047 
3.85E-
05 
5 rs11738269 CANX 5q35 0.8539 0.0293 0.1304 0.2636 
3.95E-
05 
6 rs1876155 SIM1 
6q16.3-
q21 
0.1498 0.0672 0.5046 0.9709 
3.97E-
05 
15 rs11630901 RPAP1 15q15.1 0.1481 0.0037 0.9168 0.5768 
4.07E-
05 
8 rs17211245 RDH10 8q21.11 0.3178 0.1653 0.6283 0.0366 
4.70E-
05 
 
*
 CHR = Chromosome Number; SNP = Single Nucleotide Polymorphism; MDD = Major Depressive 
Disorder; 
a, b, c
 Wald test asymptotic P-value for the association with MDD in the total, male, and female sample. 
d
 Wald test asymptotic P-value for the association of neuroticism with MDD in the total sample. 
e
 Wald test asymptotic P-value for the association of age at onset with MDD in the total sample. 
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CHAPTER 5 
DISCUSSION 
Some of the expected phenotypic dependencies of MDD are discussed in the context of 
our study findings and compared to the literature. The results of our genome-wide studies of 
MDD in the Netherlands-based sample are discussed and the newly discovered significant SNPs 
for MDD, neuroticism and age at onset of MDD will be considered. The study hypotheses 
presented in Chapter 1 are considered according to our study results. A summary conclusion is 
made and recommendations for future studies and directions for research into MDD using 
GWAS are given. 
 
Risk Factors of Major Depressive Disorder 
Findings from the Univariate Analyses 
The population used for univariate analyses contained 1,150 men and 2,206 women, 1,738 
cases and 1,618 controls. Of these, 530 men and 1,208 women had MDD affection. There were 
1,054 current smokers and 2,279 nonsmokers in the sample with a statistically significant risk for 
smokers to be diagnosed with MDD and smoking as a risk factor for MDD has been well 
reported in the literature (Husky et al., 2008).  
A significant majority (73.77%) of the sample is identified as current users of alcohol, but 
alcohol is not seen as a predictor for MDD from the multiple logistic regression analyses that 
were performed later (details in subsequent sections) on the sample. Most of the subjects in the 
study sample are either married or living with a partner while a minority reported a status of 
being single or living without a partner. The association of having familial risk for MDD in the 
study sample is significantly more (85.58%) as compared with those without any reported 
    
75 
 
familial risks for MDD (14.42%). The presence of a first degree family member affected with a 
depression disorder was identified using the Family Tree Assessment (Fyer & Weissman, 1999) 
and was a part of the CIDI-based interview that was conducted on the subjects of the sample 
during the data gathering process. The descriptive characteristics of cases and controls 
summarized earlier in Chapter 3 in Tables 1 and 2 generally agree with the results of our 
univariate analyses. 
Findings from the Bivariate Analyses  
Our study of regressing MDD as a binary trait using logistic regressions against selected 
predictors seems to be one of the few in the literature as no other study has chosen the seven 
predictors we have chosen, namely age, gender, marital status, smoking status, alcohol use, 
family risk, and NEO score. Most other studies have concentrated on age, gender, marital status 
as classic demographic variables along with such other socioeconomic variables as family 
income, educational level, and living styles. Most studies using the dbGaP data seem to be 
restricted to genotypic studies and not necessarily phenotypic in nature. Our study might be one 
of the first to look at the epidemiology of MDD using the dbGaP data. 
Our results support the findings of prior studies that female gender, smoking, and having an 
affected first degree relative are all significant risk factors for being afflicted with MDD. The 
association of family risk with an OR of 3.112 confirms the strong association of MDD within 
families and that MDD is a genetically heritable disease. The association between gender and 
MDD is shown by the 1.7:1 frequency among women as compared with men and an OR of 1.43 
(95% CI: 1.24 – 1.64). This compares well to the literature where Kessler et al. (2003) reported 
an OR of 1.4 (95% CI: 1.1 – 1.8) and Bromet et al. (2011) who recently reported a total OR of 
1.8 (95% CI: 1.6 – 2.0) in high-income countries (e.g., Belgium, France, Germany, Japan, 
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Netherlands, etc.) and low-income countries (e.g., Brazil, India, Columbia, Mexico, etc.) around 
the world. 
According to the study by Bromet et al. (2011), MDD is a significant public health concern 
across all regions of the world and is strongly linked to social conditions. Three predictors – age, 
gender, and marital status – are available as common study predictors for comparison of our 
results. Comparing their gender results with our European (in particular, the Netherlands 
population) sample the OR value of our sample (1.43) is much smaller than Bromet et al. study 
sample which is reported to be 2.3 (95% CI: 1.5 – 3.5). They categorized age into four groups – 
18-34, 35-49, 50-64, and 65+ and they also categorized marital status into five groups - never 
married, separated, divorced, widowed, and currently married. But in our data set, age is a 
continuous variable and marital status is binary and thus we cannot compare our results directly. 
Our study must reconsider age as categorical and reformat our data to reflect their four age 
groups and the regression rerun before we can compare the age as a risk factor. Their ORs for 
marital status range from 2.6 to 1.9 with ‘65+’ category being the reference at 1.0. Similarly our 
marital status OR is 3.05, but we need to categorize our marital status and the regression rerun 
before attempting any comparisons. Their ORs range from 2.7 to 1.8 with currently married 
category being the reference at 1.0.  
MDD is also comorbid with smoking as shown by an OR of 2.88 (95% CI: 2.48 – 3.35) 
which is consistent with other studies (Husky et al., 2008). Prevalence of depression among 
cases who have a first degree relative being also diagnosed with some form of MDD is shown to 
be the highest predictor (OR: 3.45 with 95% CI: 2.42 – 4.92) in our study. The family risk for 
MDD shows up as a leading predictor for MDD in the study sample from the logistical 
regression analyses. Several studies have linked chronic MDD to family history of depression 
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(Camp et al., 2005; Gonda et al., 2006; Lazary et al., 2009). Lazary et al. (2009) use a different 
phenotype called affective temperament that is measured via special instrument called TEMPS-A 
(Kesebir et al., 2005). They concluded that a crucial part of inherited factors of depression is 
mediated by affective temperament. 
In addition, both alcohol usage and being married (or living with a partner) showed a 
moderating effect with respective ORs of 0.498; 95% CI: (0.426-0.583) and 0.327; 95% CI: 
(0.275 – 0.389) for being diagnosed with MDD. These results may point to the emotional and/or 
calming (coping) effects of family bonds and alcohol. However, there are also many studies 
about alcohol usage and MDD (see Chapter 2 for details) that shows an opposite effect. 
Findings from the Multiple Variable Analyses 
The results in Table 5 show that only age as a risk factor is removed upon multiple logistic 
regression. The remaining risk factors marital status, smoking status, family risk, alcohol use and 
NEO score continue to stay significant at p = 0.028 or much below that. The corresponding OR 
values do not change much indicating minimal amounts of confounding among the risk factors. 
As shown by Tables 6, 7, and 8 the analyses with interaction effects among the three major 
predictors, gender, smoking, and family risk show little or no statistical significance. However, 
the risk factor ‘smoking status’ has been classified as a binary variable and we do not have any 
knowledge (data) of whether a person’s smoking status was pre- or postdiagnosis of being 
afflicted with MDD. Thus the major risk factors for MDD from this study that could be 
ascertained are gender, neuroticism, and family risk. 
In terms of looking at our results, the odds ratio of 1.28 and 95% CI of (1.078 – 1.602) 
gender is a significant risk factor with a modest chi-square value of 4.82 and a p-value of 0.028.  
Smoking status has an OR of 3.07 (95% CI: 2.45 – 3.87) even after adjustment for other 
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confounding variables and is a major risk factor of MDD. Looking back at the available literature 
on smoking and MDD (Chapter 2.2), female gender and prior smoking together increase the risk 
of MDD. From our results it seems that the smoking status of this particular female population 
could have been “heavy or daily” as opposed to “occasional” or “prior”.  This confirms other 
studies on smoking and MDD that were cited earlier in Chapter 2 (Cardenas et al., 2002; Gulec 
et al., 2003; Husky et al., 2008). Our results show an OR of 3.07 which is higher than the highest 
found in the Husky et al. study where the smoking females had an OR value ranging from 1.36 to 
2.52 corresponding to “prior user status” to “current daily user” status. 
Both marital status (being married or living with a partner) and alcohol use seem to be 
beneficial as indicated by their negative parameter values. However, from our earlier discussion 
in Chapter 2 alcohol use has a more complex relationship with MDD. As has been reported in the 
literature alcohol consumption when moderate could be beneficial to a person’s health, but 
specific studies showing benefits for mental health are not found in the literature. Comparing the 
OR of marital status from the bivariate analysis to the multiple variable analyses, we see a jump 
in value from 0.327 to 0.432. While both values are well below 1.0, the confounding seems to be 
beneficial and further analyses are needed to determine the particular risk factor that confounds 
marital status as a risk factor for MDD. However, as South and Krueger (2008) point out, it is the 
“marriage quality”, not just being married (which is all the information we have in our data) 
might not reveal any suggestive relationship between MDD and marital status. South and 
Krueger further point to environmental influences along with genetic influences that internalize 
stressors, which in turn affects the psychopathology. Suffice is it to say that simple odds ratios 
(albeit adjusted for confounding) may not be good indicators of possible risks that a marriage 
may bring in terms of influencing a person’s (esp. a female’s) mental disorder. In summary, the 
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genetic effects on the internalizing factor contribute to the development or worsening of MDD. 
Further discussion of this complex subject is beyond the scope of this report. 
As to be expected, the family history of MDD has a huge bearing on MDD shown by the OR 
of 3.11 (95% CI: 2.17 – 4.46) which is slightly greater than what we have found for smoking. 
Again, this association is more complex to be analyzed and results like adjusted odds ratios 
might not reflect the underlying functional relationships. MDD is known to be heritable (up to 
70% as some studies have shown) and both twin and family studies have contributed heavily and 
will continue to do so in the future as genetic studies unearth more specific genetic regions and 
SNPs where the predisposition to MDD may lie and how any pattern of inheritance could be 
mapped. Multiple variable analyses may not throw any more light on this risk factor than the 
simple bivariate analysis discussed earlier. However, our initial Hypothesis 1 (stated in Chapter 
1) is true as has already been shown in the literature; i.e., being female, smoking, and family 
history are all major risk factors for MDD. 
 The effect of NEO Score has been positive but the relationship between MDD and 
neuroticism was further evaluated using GWAS methods by treating it as an endophenotype or a 
quantitative trait of MDD. The results from our study are further discussed in the next section. 
 
Genetic Association Analyses 
We conducted genome-wide studies of two MDD related phenotypes, namely, neuroticism 
and age at onset. Results from each of these studies are discussed separately below. 
Genome-Wide Association Analysis of Neuroticism 
A quick search in the OMIM and Entrez Gene databases for the implicated genes did reveal 
some significant gene function or association with some mental disorders. The most significant 
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association of neuroticism is with the gene TMPRSS9 containing the SNP rs4806846 (p = 
7.79x10
-6
) at 19p13.3. This gene has been associated with the regulation of physiological and 
pathological phenomena on the cell surface and has been implicated in congenital or childhood-
onset form of deafness (Hayama et al., 2007). Functionally, Polyserase-1 transcripted from the 
gene TMPRSS9 has alternative transcripts serase-1B and serase-2B (Okumura et al., 2006). 
These have been found to be novel type II transmembrane serine proteases which may play a role 
in regulating physiological and pathological phenomena on the cell surface. In other functional 
studies, TMPRSS9 has been seen to possess a unique structure with three tandem serine protease 
domains (serase-1, 2, and 3) (Cal et al., 2003). 
The second best SNP rs220549 in the GRIN2B gene at 12p12 has been associated with 
Schizophrenia (Doi et al., 2009), Bipolar Disorder (Fallin et al., 2005), Alzheimer’s disease 
(Stein et al., 2010) and Obsessive Compulsive Disorder (OCD) (Arnold et al., 2009). 
Functionally, GRIN2B is associated with Glutamate and N-Methyl D-Aspartic acid (NMDA) 
receptors and have been found to participate as an excitotoxin for an operant behavior in 
laboratory animals (Watkins et al., 2006). Both linkage and association studies of GRIN2B have 
shown strong associations with Schizophrenia and Bipolar Disorder (Doi et al., 2009; Fallin et 
al., 2005) in Ashkenazi Jewish population samples. A significant (p = 0.04) association of 
GRIN2B has been identified by Arnold et al. (2009) with a decreased glutamatergic 
concentration in the anterior cingulate cortex (ACC) that has been consistently implicated in 
OCD. In addition, the NMDA protein encoded by the gene GRIN2B and is involved in learning 
and memory along with excitotoxic cell death has age-dependent prevalence in the synapse and 
is already a therapeutic target in Alzheimer’s disease (Stein et al., 2010). 
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The third best neuroticism associated gene SGCA has been associated with limb girdle 
muscular dystrophy, type 2D (LGMD2D) (Mendell et al., 2010) and embryonal 
rhabdomyosarcoma in laboratory mice (Fernandez et al., 2010).  In terms of association, 
mutations in the SGCA gene may have caused LGMD2D in patients who were then subjected to 
successful early phase gene therapy using adeno-associated virus (AAV) gene transfer under 
control of a muscle specific promoter. Long-term, sustained gene expression of alpha-
sarcoglycan may result in an effective treatment for LGMD2D (Mendell et al., 2010).  
Functionally, the dystrophin-associated glycoprotein (DAG) complex is a group of muscle 
proteins whose loss gives rise to muscular dystrophy. In laboratory mice lack of alpha-
sarcoglycan (expressed by SGCA as a member of the DAG complex) results in a spontaneous 
development of muscle-derived embryonal rhabdomyosarcoma (Fernandez et al., 2010). 
Among other associated SNPs in Table 11, we found the SNP rs8068962 (p = 3.32x10
-5
) in 
the gene STX8 at 17p12 associated with the Crohn’s disease (AceView, 2011). Two other 
disease associated SNPs were – rs2344734 (p = 3.61x10-5) in the gene NEB associated with 
Nemaline Myopathy (Wallgren-Petterson et al., 2007), and rs6065392 (p = 5.02x10
-5
) in the gene 
ZHX3 associated with Primary Glomerula disease (Liu, Clement, Kanwar, Avila-Casado, & 
Chugh, 2006). In fact, Wang et al. (2009) and Wilson et al. (2003) have suggested predictive 
association of neuroticism with dementia and Alzheimer’s disease (AD) respectively. High 
neuroticism has been associated with greater risk of dementia, while an active and socially 
integrated lifestyle may modify the risk for dementia. Wang et al. (2009) conducted a 
prospective study of 506 older people for 6 years to conclude that a combination of high 
extraversion and low neuroticism is the personality trait required to maintain a low risk for 
dementia (Wang et al., 2009). Wilson et al. (2003) used NEO-FFI neuroticism score to assess the 
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disposition to experience psychological distress in a population of older Catholic nuns, priests, 
and brothers participating in a Religious Orders Study of aging and Alzheimer’s disease. Their 
findings showed the tendency to experience psychological distress predicted development of 
incident AD and rate of cognitive decline (Wilson et al., 2003). 
In addition, as shown by Table 12, several of these significant SNPs in the region showed up 
as being significant for ASPD in an Australian sample (OZALC study) thus linking neuroticism 
and antisocial behavior (Ducci et al., 2008; Schmidt et al., 2000; Wang et al., 2011). However, 
further studies and replications are required before we can establish firm genome-wide 
associations between neuroticism and anti-social behavior. 
An analysis of the statistical power of our study using QUANTO software shows a power of 
96% for the main effect using the neuroticism as a quantitative trait at a mean value of 39.3 ± 
8.0, an allele frequency of 0.05, and a marginal R
2
 of 0.005. The main effect regression 
coefficient was derived to be 1.8353. Looking back at our Hypothesis 2 (see Chapter 1), we 
stated that neuroticism as a quantitative trait to conduct genome-wide association analysis may 
increase the statistical power. A high statistical power of 96% that was achieved for this 
particular sample population of Dutch origin in the Netherlands makes our hypothesis true. 
However, many more replication studies are needed using other human populations before we 
can confirm our hypothesis. 
To our knowledge, this is the first GWA analysis of neuroticism as a quantitative trait of 
MDD. Identification of a common genomic region between neuroticism in the NESDA 
population and ASPD in the OZALC population may signal possible association between 
neuroticism and ASPD that needs to be further investigated.  
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Gene x Gender Interaction Analysis of Neuroticism 
According to literature the HMCN1 gene has been associated with gene x environment 
interaction in patients presenting atherosclerosis and two of the intervening environmental 
factors have been gender and smoking (McGeachie et al., 2009). Another implication of the gene 
HMCN1 is in age-related macular degeneration (AMD) that affects the renal functions 
(Thompson et al., 2007). The authors report that the association of HMCN1 is not phenotype-
specific and it appeared to influence the longitudinal rate of change of AMD while also 
accounting for other risk factors like family history.  
The gene SNTG1 encodes a protein specifically expressed in the brain and its transcript 
variants have not been fully described, nor has their full-length nature been determined as of this 
writing. The gene has also been implicated in personalized smoking cessation studies (Rose, 
Behm, Drgon, Johnson, & Uhl, 2010) in terms of affecting the dosage of nicotine as an 
environmental variable. The third most significant SNP rs2612437 (p = 9.3x10
-6
) is in the region 
between genes MAP2K4 and MYOCD. The gene MAP2K4 encodes a dual specificity protein 
kinase which is an activator of receptors to stressful signals from the environment, while the 
gene MYOCD encodes a nuclear protein expressed in heart, aorta and other smooth muscle 
containing tissues. 
Thus so far, no specific or direct role of the implicated gene x gender interaction of 
neuroticism genes have been connected to MDD, but they all seem to have some functional role 
in the gene x environment interaction effects. Further studies and more functional analyses are 
required to determine the specific roles of these genes. Detection of gene x gender interactions 
provides a preliminary basis for the second part of Hypothesis 2 (stated in Chapter 1). However, 
we again caution the need for replication studies using other samples before we could generalize 
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our results as a determinant for the observed preponderance of higher prevalence of MDD in 
females. In fact, the study of gene x gene and gene x environment interactions in GWAS is 
extremely important before declaring any compelling associations. 
 In a perspective written by The Psychiatric GWAS Consortium Steering Committee (2009), 
the authors recognize a new type of study called “integrated mega-analysis” that is different from 
the conventional meta-analysis. Mega-analysis uses individual-level genotype and phenotype 
data as opposed to summary data (such as Odds Ratios used in meta-analyses) and integrated 
mega-analyses of all GWAS data might lead us toward the etiology of psychiatric diseases such 
as MDD. According to the committee a conventional definition of MDD with the identification 
of one or more compelling associations with a SNP, haplotype, or copy number variant could 
become the “holy grail” of psychiatric genetics. 
Genome-Wide Association Analysis of Age at Onset of Major Depressive Disorder 
The SNP rs734253 in gene GPR143 was the best SNP with the strongest p-value at p = 2.54 
x 10
-12
 along with three more genome-wide significant SNPs - rs6641545 in the gene ASS1P4, 
rs5983118 in the gene MXRA5, rs6654462 flanked by the genes MAGEC1 and MAGEC2. In 
addition, the gene PPARGC1B contained four SNPs (rs32589, p = 4.72x10
-6
; rs10515638, p = 
9.77x10
-6
; rs26125, p = 1.04x10
-5
; rs17110375, p = 1.42x10
-5
) of high significance (p < 10
-4
) 
along with the gene GRIK4 which contained one SNP rs3016415 also at high significance (p = 
3.5x10
-5
). 
While the top four SNPs have been found to be of GWAS significance, the associated genes 
are novel in that none of them have been implicated in any specific disease association earlier. 
Some passing observational references have been made in the gene databases, such as, the 
MAGEC1/2 genes are seen in human melanoma and the GPR143 has been implicated in Ocular 
    
85 
 
albinism. But, no direct association with MDD or any other mental disease has been made for 
these novel genes. 
A quick search in the gene databases revealed that the gene PPARGC1B has been associated 
with obesity, metabolism, and body energy regulation (e.g., performance of athletes) and the 
gene GRIK4 which has been implicated in neuronal signaling (Joslyn, Ravindranathan, Brush, 
Schuckt, & White, 2010) and in an individual’s performance on standardized tests (Cirulli et al., 
2010). The gene GRIK4 has been implicated for strong remission of depression in depressive 
patients undergoing anti-depressant therapy (Horstman et al., 2009). Functionally, GRIK4 gene 
encodes a protein that belongs to the glutamate-gated ion channel family. Glutamate functions as 
major excitatory neurotransmitter in the central nervous system through activation of ligand-
gated ion channels and G-protein coupled membrane receptors. 
Many genetic linkage studies have been undertaken in the context of recurrent and early 
onset MDD and the early age at onset has been considered as below the age of 31. Separate 
adolescent studies have also been done and thus the current literature seems to have dealt with 
age at onset under two categories – adolescent MDD and adult MDD.  
Many associations have been made in the literature between early or late age at onset of 
MDD and risky behaviors like alcohol abuse and cigarette smoking (e.g. Sund, Larsson, & 
Wichstrom, 2011) and a study of brain anatomy (volume of amygdala) of older patients with 
late-life depression (Burke et al., 2011). However, other than a study by Shi et al (2011) the 
current literature does not show specific GWAS of AAO in MDD. The Shi study excludes 
lifetime MDD and also focuses on people who were diagnosed with MDD before the age of 31 
years.  
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Thus, the current study reported in this dissertation seems to be first of its kind (population-
based study of age at onset of both adolescent and adult MDD) with a large 18-65 years MDD 
cohorts which has found four novel genes (GPR143, ASS1P4, MXRA5 and two SNPs between 
MAGEC1 and MAGEC2) with GWAS significance. It is hoped that future studies will be able to 
replicate these GWAS significant MDD implicating genes in other populations in order that 
AAO as a quantitative trait of MDD can become a basis for further elucidation of MDD and its 
genetic variants. 
The above finding of novel genetic variants for MDD using age at onset as a quantitative trait 
means that our Hypothesis 3 (stated earlier in Chapter 1) is true. Again, we hasten to caution that 
replication in other populations and specific functional associations need to be ascertained before 
implicating these novel genes for MDD. 
 
Strengths of the Study 
The main strength of this study is that it is the first GWA study of the MDD related 
quantitative traits of neuroticism scores and age at onset of MDD. Next, we have looked at the 
gene x gender interactions of neuroticism associated with MDD cases and have unearthed some 
novel genes and associated SNPs by the analysis of age at onset as a quantitative trait. These new 
genes and their associated genomic regions can further be examined for functional significance 
and other tag SNPs that may have been reported by other researchers for various mental 
disorders and other complex diseases.  
The gender differences we have found in the differing significant SNPs (p < 10
-4
) for 
Neuroticism in men and women with MDD and the clear interactions between gene and gender 
for the mean NEO scores (see Figure 5 in Appendix C) show the strength of using quantitative 
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traits in GWAS. Elucidating the genetic basis of MDD by exploring other quantitative 
phenotypes of MDD might lead to a narrowing of the set of genes that might be implicated for 
MDD. 
Discovery of novel genetic variants of MDD by the use of another quantitative trait (namely, 
age at onset of MDD) points to possible first steps in understanding the etiology of MDD in 
adolescents and young adults. Knowing the fact that young adults in the age group of 18-29 
(Kessler et al., 2003) have one of the highest ORs (3.0) for MDD, understanding the genes 
implicated by the age at onset of MDD further is an important public health undertaking in order 
to craft early interventional strategies for that group of young adults. Furthermore, finding 
common and significant (p < 0.05) genetic variants in two different populations (as we did for 
neuroticism in the NESDA and ASPD in the Australian sample) might lead us to common 
biological functional underpinnings that might one day help us in identifying newer 
interventional strategies based on the specific functional proteins and signaling pathways.  
While we are still years away from elucidating the etiology of MDD, adding new and 
significant biomarkers (SNPs and genetic regions) to the existing databases may pave the way 
for detecting and/or understanding of how genes can affect the development of MDD in 
vulnerable populations. 
As we have seen from our limited results of MDD vulnerability, both gender and family risks 
must be studied further to look for possible public health intervention strategies to prevent early 
onsets of MDD, progression from temporal to lifelong suffrage of MDD, and suicidal deaths 
from MDD. Genetic and genome-wide association analyses are only the first step in terms of 
using the power of newer genetic and bioinformatics technologies in order to enhance the 
epidemiological methods available for combating MDD in our society. 
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Limitations of the Study 
A number of limitations must be recognized in this study. This is a preliminary study looking 
at neuroticism as an endophenotype for MDD and as such needs to be replicated in several other 
samples. Other than showing some associations at suggestive level (p < 5x10
-4
), not all 
implicated SNPs reach the GWA significance level (p < 5x10
-7
). Our findings must be 
interpreted with caution because of limitations of sample size and power.  
While the initial phenotypic analyses using logistic regression methods confirmed the major 
risk factors for MDD (female gender, marital status, etc.) further work needs to be done by 
categorization of certain risk factors as age (in terms of specific age groups), marital status (in 
terms of specific statuses as being single, widowed, same sex partner, etc.), and alcohol use (in 
terms of teetotaler, casual drinker, moderate consumer, heavy drinker, and abuser). The alcohol 
and/or tobacco use as a risk factor for any medical condition are in general viewed as being 
contentious and both risk factors are highly complex to analyze. Our study does not adequately 
address these two risk factors for MDD. 
Genome-Wide studies have been criticized for not being able to find main effects of genes on 
complex diseases such as MDD. Thus, this study must be expanded to include investigations of 
specific vulnerable genetic regions (esp. within families) by using the latest New Generation 
Sequencing (NGS) technologies, albeit with added expense to procure new equipment and 
design new strategies to limit research for functional understanding of the known genes. 
Conclusions and Further Recommendations 
Our results showed female gender, family history of MDD, and smoking as major risk factors 
for MDD, findings that are consistent with past studies. We found several significant SNPs (at p 
< 10
-4
) for the association of neuroticism in MDD and significant gene x gender interactions 
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implicating several new genes – TMPRSS9, GRIN2B, SGCA, HMCN1 and SNTG1. More 
interestingly, we found four novel genes at genome-wide significance (p < 5x10
-7
) for age at 
onset association with MDD. These novel genes are – GPR143 (p = 2.54x10-12), ASS1P4 (p = 
9.75x10
-10
), MXRA5 (p = 5.67x10
-8
), and the genomic region between MAGEC1 and MAGEC2 
(p = 3.99x10
-7
). 
Much work remains to be done in the elucidation of genetic variations and the etiology of 
MDD as a complex and chronic disease that affects millions of people around the world and 
poses as a major global burden of disease. The results of our study contribute to expanding the 
genetic basis of MDD. Replication studies in other population in order to elucidate the genetic 
variants of MDD are needed. 
A few recommendations for further study are in order – 
 Conduct replication studies of other non-European populations that are vulnerable to 
MDD using neuroticism and age at onset as quantitative traits. 
 Discover other mental disorders that have same or similar genomic regions as what 
we have found and study the interrelations and gene functionality that might explain 
further biological mechanisms that make it possible for MDD to be inheritable in and 
across families at rates of 40%-70%. 
 Use Haploview and other modern genetic software tools to find the tag SNPs from the 
significant SNPs found in our study. 
 Procure funding for exploring the pertinent genomic regions significant for 
neuroticism and age at onset using Next Generation Sequencing of human 
chromosomes 1, 8, 12, 17, 19, and 23 (or X chromosome). 
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APPENDICES 
APPENDIX A 
A1. Lifetime prevalence of Major Depressive Disorder and Age at Onset distributions 
The literature indicates that until 2005 little was known about the lifetime prevalence or age 
at onset of a number of DSM-IV disorders including MDD. Kessler et al. (2005) conducted a 
study of 9282 English-speaking, nationally representative Americans aged 18 and older (from 
the NCS-R sample) in order to estimate the distribution of lifetime prevalence and age at onset of 
DSM-IV disorders. Their findings reported that about half of Americans will meet a DSM-IV 
disorder criterion sometime in their life, with the first onset usually in childhood or adolescence. 
Thus any intervention to prevent or treating early the symptoms of MDD must be focused on the 
youth according to Kessler et al. (2005). 
The results from Kessler et al. (2005) epidemiologic study indicate that the lifetime 
prevalence estimates are as follows –  
 
Table A1-1 
 Lifetime Prevalence Estimates 
Age Group Prevalence % (SE) 
Total sample (18 – 60+) 16.6 (0.5) 
Age 18 - 29 15.4 (0.7) 
Age 30 - 44 19.8 (0.9) 
Age 45 - 59 18.8 (1.1) 
Age over 60 10.6 (0.8) 
Ages at selected percentiles on the standardized age at onset distributions of MDD with 
projected lifetime risk at age 75 are as follows –  
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Table A1-2 
Projected Lifetime Risk at Age 75 
Projected Lifetime Risk 
at age 75; 23.2% (0.6 SE) 
Actual Age 
Percentile 5 12 
Percentile 10 14 
Percentile 25 19 
Percentile 50 32 
Percentile 75 44 
Percentile 90 56 
Percentile 95 64 
Percentile 99 73 
The authors of the above study, however, point to four biases that should be noted -   
 1. People with a history of mental illness are less likely to participate in the study. 
 2. Well-known bias of underreporting embarrassing behaviors. 
 3. Estimation of lifetime risk was based on the assumption of constant conditional 
risk of first onset in a given year of life among people of different ages at 
interview. 
 4. Recall bias of age at onset. 
Given the enormous public health consequences of MDD, the above observations should lead 
us to thinking about interventions early in childhood and adolescent years and prevention of 
MDD and its comorbidities (Kessler et al., 2005). 
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A2. An Overview of WMH-CIDI 
The World mental Health (WMH) Composite International Diagnostic Interview (CIDI) is a 
collection of a screening module and has 40 sections with 22 sections that focus on diagnoses, 
four sections on functioning, 2 sections on treatment, 4 sections on risk factors, 7 sections on 
socio-demographic correlates, and 2 sections on methodological factors. A computer-based 
version of the interview is available with direct data entry software using a keyboard. Diagnoses 
based on ICD-10 and DSM-IV criteria are generated from the WMH-CIDI software. In addition, 
CDROM-based training materials are available to teach the interviewers how to administer the 
interview and teach the supervisors how to monitor the quality of data collected. A brief 
description of the details (Kessler & Ustun, 2000) is presented below.  
The diagnostic survey methodological issues consists of question and task comprehensions, 
motivation, ability to answer diagnostic questions accurately, section to review one’s lifetime, 
details of Part I and Part II diagnostics, and the expanded section to include such lifetime factors 
as the socio-economic status (SES), family, and childhood experiences. The aim of the interview 
is to obtain valid information about the prevalence, correlates, and unmet needs for treatment of 
mental disorders in the general population as well as to determine the treatment adequacy and the 
societal burden of mental disorders. 
Question comprehension  
Answering structured interview questions that are ambiguous is easily misconstrued by more 
than 70% of the respondents as was shown by Belson (1981) and others (Oksenberg et al., 1991). 
The problem in surveys is that the flow of questions is predetermined by the researcher and the 
normal rules of conversation (e.g., give-and-take) do not apply and this is compounded when the 
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topic of discussion is the emotional experiences of the respondent. Four discriminating features 
among the high and low levels of misunderstandings are complexity, vagueness, multiple 
interpretations of an odd experience, and contextual. The solution arrived to avoid the problems 
in question understanding was to breakdown the complex questions into simpler subquestions.  
Task comprehension  
Second type of misunderstood response in CIDI came from people who did not understand 
what they were being tasked to do when a response needed a considerable thought. Cannell et al. 
(1981) has shown that this problem could be solved by instructing respondents to answer the 
question completely and accurately. The stem question preceding questions that need clear 
comprehension of the task at hand must be timed properly and also placed appropriately within 
the survey along with a preface – “The next question may be difficult, so please take your time 
before answering”.  
Motivation  
Getting valid responses needs motivation on the part of the respondent and thus motivational 
instructions and contingent reinforcement during the interview (e.g., “You answered that very 
quickly. Was there anything else, even something unimportant that you want to add?”) are 
needed to enhance the validity of the responses. CIDI uses this type of contingent reinforcement 
a part of their training materials developed for the WMH surveys. Another motivational aspect of 
getting the respondent demur explicitly or tacitly work hard to give an honest answer is a part of 
the common understanding between the interviewer and the respondent (e.g., Clark et al., 1992; 
Loftus & Palmer, 1974).   
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Ability to answer accurately  
Episodic and semantic memories play a role in influencing the respondent’s accuracy in 
answering questions. For example, the respondent may have a semantic memory of what panic 
attacks are like, but after having many such attacks in one’s lifetime, one may not be able to 
recall one attack accurately. Research has shown that people are more likely to recall episodic 
memories more accurately than the semantic memories (say, from panic attacks) that are 
frequent, typical, and regular. Thus, asking questions without knowing the limits of one’s 
memory should be based on episodic memory for accuracy, whereas, clarification must precede 
any questions about semantic memories. Thus, the designers of WMH-CIDI used pilots where 
respondents were debriefed with an explicit eye towards pinpointing questions that were difficult 
to answer. 
Lifetime review section  
One of the most important aspects of the CIDI is the life review cycle that is administered at 
the beginning of the interview. This will both motivate and facilitate active memory search in 
answering the diagnostic stem questions. This modification to the earlier CIDI led to a 
significant increase in the proportion of respondents who endorsed the diagnostic stem questions 
(Kessler et al., 1998). While some upward biasing questions were raised from some early 
international surveys (e.g., as much as 50% increase in lifetime criteria for ICD or DSM mental 
disorders), clinical calibration proved otherwise leading to add a clinical significance criterion to 
many disorders in DSM-IV. However, some critics have argued for including some subthreshold 
cases (e.g., Merikangas et al., 2003) in the definitions for mental disorders. Research-wise this 
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might be important because full exploration of the continua rather than the currently established 
threshold guidelines yields greater power in studies of genetic and environmental risk factors 
(Benjamin et al., 1998). Further discussion on subthreshold disorders, symptom persistence and 
severity, internal and external impairments, and the ranking of physical and mental disorders are 
available in Kessler & Ustun, 2000. 
Part I and Part II diagnoses  
The WMH-CIDI is an elaborate instrument that takes up as many as 2 full hours to complete 
the interview. In practice this would entail complications in order that the interview is done in 
two parts – Part I and Part II. Part I includes all core diagnostic assessments and those who report 
having no lifetime history of disorder are terminated at this midpoint of the interview. Part II is 
completed by those diagnosed as being with lifetime disorder issues. Further elaboration of 
subsampling of noncases to be included in Part II and other case-control and statistical power 
issues are more fully discussed in Kessler and Ustun, 2000. 
Other factors  
The main reason behind developing WMH-CIDI was to expand a previous version of the 
instrument and include assessments of risk factors, consequences, and treatment. Accordingly, 
socio-demographics, treatment and pharmacoepidemiology, nonspecific psychological distress, 
family burden, and childhood experiences are all included in specific subsections of the 
interview. Socio-demographics include such predictors (or, risk factors) as age, gender, race, 
educational attainment, marital status, and employment status. The idea here is to include the 
dynamic information about achieved statuses in the interview schedule. Treatment and 
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pharmacoepidemiology sections assess both internally and externally the patterns and predictors 
of delays in initial treatment after first onset of disorder, lifetime hospitalization, and the type of 
professionals the respondents have sought and seen. Nonspecific psychological distress 
information gives the frequency and a scaled score from a screen for serious mental illness (SMI) 
30 days before the interview and in the worst month of the past year. This information would be 
very useful as an inexpensive mental health needs surveillance tool for public health 
professionals. While the assessment of the respondent gives rise to excellent understanding of 
how mental disorders affect the people with the disorders, it ignores the patient’s family. Thus, 
the enormous family burden needs to be measured and a special section has been introduced to 
assess the same in WMH-CIDI. After inquiring about a network of first degree relatives, the 
respondent is asked about 12 serious health problems (cancer, heart problems, memory problem, 
mental disorders like schizophrenia, manic depression, etc.) of those first order relatives. The 
data collected here also helps in laying the ground work for any family-based genetic studies at a 
later date. Finally, such childhood experiences as having a single parent or nonbiological parents, 
trauma caused by authoritarian, overprotective or neglectful parents, any sexual abuse, etc. are 
collected by a special section at the end of the CIDI interview. Separate assessments of parental 
depression, panic disorder, general anxiety disorder, antisocial behaviors, and substance-abuse 
disorders are made here. 
The results from the WMH-CIDI interview are summarized in terms of quantitative scores 
that are stored in a database and a final qualitative diagnosis of MDD is reached by a computer 
program.  
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APPENDIX B 
Brief Summary of the Genomics and Genome-Wide Association Analyses Literature 
Considering that the human genome was fully sequenced (i.e., over 90% of the functional 
genome) in 2004 (International Human Genome Sequencing Consortium, 2004), and the first 
GWAS of seven common diseases was published in 2007 (Wellcome Trust Case Control 
Consortium, 2007), the literature of GWAS of MDD is rather limited. However, the 
pathophysiology of MDD at genetic and molecular levels has been studied extensively in the past 
3 to 5 years and many genes (and/or gene regions) have been implicated to be strongly associated 
with MDD and its related phenotypes.  
In addition to the complete sequencing of the functional human genome, the International 
HapMap project, which was a collaborative project started in 2002 and completed in 2009, has 
given us the ability to search the entire human genome for genetic variants. The HapMap project 
was a collaborative effort between researchers in Canada, China, Japan, Nigeria, UK, and the US 
and used samples from four groups as follows: 
 30 adults-and-both-parents trios (90 people) from Ibadan, Nigeria (YRI) 
 30 trios (90 people) US residents of northern and western European ancestry (CEU) 
 44 unrelated individuals from Tokyo, Japan (JPT), and 
 45 unrelated Han Chinese individuals from Beijing, China (CHB) 
The genotyping of these diverse human populations has resulted in a SNP database 
(dbSNP) of the complete human genome that has provided over 27 million SNPs for use in 
genetic research and Genome-Wide studies. 
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A brief summary of definitions, post-genomic era accomplishments, consensus, challenges 
and uncertainties, positives and perils, and phenomics – the systematic study of phenotypes on a 
genome-wide scale are discussed briefly below. 
Definitions  
In recent years (since 1980s), many new areas of genetics research have emerged, and thanks 
to the completion of sequencing the known functional human genome in 2004 there has been an 
even newer emergence of other ‘omics era. Some of the more important areas of research and the 
terminology attributable to this new research are –  
 Public Health Genomics – Centers for Disease Control and Prevention (CDC) defines 
Public Health genomics as an emerging field of study that assesses the impact of 
genes and their interaction with behavior, diet and the environment on the 
population’s health (Centers for Disease Control and Prevention, n.d.).  
 Genetic and Molecular Epidemiology – Morton defines this as “a science which deals 
with the etiology, distribution, and control of disease in groups of relatives and with 
inherited causes of disease in populations” (Morton, 1982). It is closely allied to both 
molecular epidemiology and statistical genetics, but these overlapping fields each 
have distinct emphases, societies, and journals. 
 Gene x Gene and Gene x Environment interactions – When two or more genes 
interact to produce a single phenotype, gene x gene interaction is said to have taken 
place. Genes may also interact with an environmental factor such as gender and 
alcohol or tobacco usage to produce phenotypes that might be different than that 
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would have resulted from the influence of the gene alone or with other genes (gene x 
gene interaction). In mental disorders many normal physiological conditions such as 
blood pressure and cognitive abilities such as intelligence probably result from the 
combined action of multiple genes, each producing a small effect together with a 
variety of environmental factors (Tsuang et al., 2004). 
 Genotype-phenotype databases – The genetic information is described in terms of the 
sequence of nucleotides (A, C, T, G) comprising the DNA and the most common 
form of genetic variation is in terms of a single nucleotide polymorphism (SNP). In 
concert with the rapid availability of several genotyping technologies, the systematic 
interrogation of the whole genome has become possible (Chanock et al., 2007). A 
compilation of these varying genetic sequences of a specimen from an organism 
(including the human) in an orderly way into a database represents a genotype 
database. The establishment of an association between a genotype and a phenotype 
constitutes a map, which when compiled into a database of associations would 
constitute a phenotype database. Some of the well-known examples of genotype and 
phenotype databases are – dbGaP (Database of Genotypes and Phenotypes), a 
publicly available database for well-known diseases from NIH, GWAS Central, 
containing the most comprehensive collection of summary level p-value GWAS data. 
Also, dbSNP, the Single Nucleotide Polymorphism Database is a free public archive 
for genetic variation within and across different species developed and hosted by the 
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National Center for Biotechnology Information (NCBI) in collaboration with the 
National Human Genome Research Institute (NHGRI). 
 Proteomics – A new branch of genomic sciences involving the large-scale study of 
proteins, particularly their structures and functions (Anderson & Anderson, 1998). 
 Systems Biology and Metabolic Modeling -  Kell (2006) opines that – “systems 
biology involves an iterative interplay between more or less high-throughput and 
high-content ‘wet’ experiments, technology development, theory and computational 
modeling, and that it is the involvement of computational modeling, in particular, in 
the process that sets systems biology apart from the more traditional and more 
reductionist molecular biology”. Simply put, metabolic modeling consists of studying 
metabolism at a molecular level using sophisticated computer-based algorithms to 
determine the changes in the concentrations of enzymes (and the transcripts that 
encode them) that have substantial effects on the concentrations of metabolic 
intermediates. 
 Bioinformatics and Biobanks - In simple terms, Bioinformatics is the application of 
computer science and statistics to the field of molecular biology. Since the 1980’s the 
field of bioinformatics has grown to include the areas of genetics, genomics, and 
DNA sequencing, while including creation and advancement of databases, 
algorithms, computational and statistical techniques, and theory to solve problems 
arising from the management and analyses of biological data (Hogeweg, 2011). 
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Biobanks are the natural evolution of bioinformatic databases to store and document 
access to biological samples and donor information (Macleod et al., 2009).  
 Epigenetics - Epigenetics is the study of heritable changes in the phenotype or gene 
expression by something (usually environmental) other than changes in the DNA 
sequence (Holliday, 1990). 
 Next Generation Sequencing - The genome sequencing efforts started back in 1991 
and they entailed a laborious radiation-based method. According to Mun-Keat Looi 
(2009), it used to take half a million British pounds (£’s) and 3 years to generate one 
bacterial genome sequence. Now one can do 100 bacterial genomes with a single run 
and newer technologies can do things that were inconceivable 2 or 3 years ago. 
Without going into all the details (Jostins, 2009; Mun-Keat Looi, 2009), the newer 
sequencing techniques use repeated cleaving (i.e., cutting up the DNA into 
fragments), reading the base (by recognizing a specific colored dye terminator), and 
moving to the next base in sequence without moving the piece of the segmented DNA 
itself, but regenerating the whole segment in place. By having the DNA cut up into 
several hundreds or thousands of contiguous pieces (called beads) in an array and 
using automated techniques, machines are now able to read one gigabase of DNA 
sequence in a couple of days at a cost of $0.02 per 1000 bases. 
Post-genomic era accomplishment  
Lesch (2004) summarizes the post-genomic era research into the genetics of depression as 
follows: 
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 A predominant role in individual differences in depression-related traits (i.e., 
phenotypes) is confirmed to be played by the variation in genetic expression 
among individuals. 
 Functional Neuroimaging has substantiated the gene-phenotype correlations. 
 Concept of gene networks controlling brain development has been recognized. 
 Gene-environment interactions in humans and animal models give rise to both 
complexity of traits and establishment of specific phenotypes. 
Hirschhorn and Daly (2005) acknowledge that genetic association studies offer a potentially 
powerful approach for mapping causal genes with modest effects but also warn that only a small 
number of genes can be studied at one time and that the contributions made by any single gene 
are small. They also note the post-genomic era accomplishments in terms of deposition of 
millions of SNPs into public data bases, rapid improvements in genotyping technology, and the 
completion of the International HapMap Project (Gibbs et al., 2003).  
Consensus, Challenges, and Uncertainties  
The first wave of GWAS has improved our understanding of the genetic basis of many 
complex traits such as diabetes, prostate and breast cancers, inflammatory bowel disease, and 
many loci implicating these diseases have been found (McCarthy et al., 2008). In addition, the 
National Cancer Institute (NCI) and National Human Genome Research Institute (NHGRI) have 
published an updated list of GWAS as a catalog which is available on their web sites. Several 
common variants influencing such continuous traits as lipids, height, and fat mass have also been 
found (Diabetes Genetic Initiative, 2007; Frayling et al., 2007; Katheriresan et al., 2008; Sanna 
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et al., 2008; Weedon et al., 2007). However, many challenges remain and compelling signals 
highlighting previously unsuspected biology and known variants of implicated genes explain 
only a fraction of the observed familial aggregation, thus limiting potential application for early 
interventions. Much work needs to be done to obtain a complete inventory of variants at each 
locus and determine the molecular mechanisms that are in play in order to determine the disease 
risk. In addition, the joint effects of the gene and the environment need to be modeled and further 
analyses are needed to determine the complete range of susceptibility variants to explain the 
clustering in families and the multifactorial nature of the complex traits (McCarthy et al., 2008). 
Positives, Protocols, and Perils  
Neale and Purcell (2008) discuss GWAS in a more practical way of detecting phenotypic 
associations of modest effect contrasting it from the previous linkage and candidate gene 
approaches. Accordingly, they look at GWAS as being a study of hundreds of thousands of 
single nucleotide polymorphisms (SNPs) in thousands of individuals looking to comprehensively 
survey common genetic variation. More importantly, they outline some key analytic 
considerations, study design, quality control, and data cleaning along with analysis and 
replication of results in other samples. 
Presently, two major initiatives, one in UK (Wellcome Trust Case Control Consortium – 
WTCCC), and one in the US (Genetic Association Information Network – GAIN) are generating 
GWAS data. The UK study is comprised of 2,000 case sample cohorts for each of the following 
diseases – Tuberculosis, coronary heart disease, types 1 and 2 diabetes, Crohn’s disease, 
rheumatoid arthritis, bipolar disorder, heart disease, and hypertension. The US study, on the 
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other hand, has generated approximately 600K markers for schizophrenia, bipolar disorder, 
diabetic nephropathy, MDD, ADHD, and psoriasis. The data used in this dissertation also come 
from the GAIN initiative in the US that can be found at  
http://www.fnih.org/gain2/home_new.shtml. 
Numerous resources (SNP chips, online resources, collaboration, and consortia) have been 
instrumental in making GWAS popular in recent years. Commercially available SNP chips are 
being offered by Illumina, Affymetrix, and Perlegen to provide genotyping services for 
individuals and/or families. A number of internet-based resources provide information for 
accessing and understanding the results of a GWAS – for example, the National Center for 
Biotechnology Information (NCBI - http://www.ncbi.nlm.nih.gov) hosts dbGaP, the database of 
Genotypes and Phenotypes. Other resources include linking information to professional and 
peer-reviewed articles in PubMed (a searchable index of publications), GenBank (a genetic 
sequence database), and Entrez (a search engine for nucleotide, protein, structure, taxonomy, 
genome, expression, and chemical databases). In addition, a number of shared controls sets (for a 
case-control study) are available from WTCCC and GAIN (pending an application process).  
Neale and Purcell (2008) opine that a successful GWAS is through increasing sample size 
that enables detection of variants of small effect. Pooling of case samples from across the UK 
and US as well as drawing from the experience of analysts, geneticists, and clinicians on major 
collections provide additional benefits. Some examples for the collaborative work include major 
type 2 diabetes projects DGI, FUSION, and Novartis (Saxena et al., 2007), the International 
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Multi-center ADHD Genetics (IMAGE) project (Bookes et al., 2006; Kuntsi et al., 2006), and 
the NTR and NESDA biobank project (Boomsma et al., 2008).  
Some of the perils that come with GWAS are selection and use of computer software 
packages, study designs, and data quality control. Neale and Purcell (2008) describe a number of 
issues arising out of software selection, design of a required study, and cleaning up of data. 
Software packages like PLINK (Purcell et al., 2007), principal components analysis (Price et al., 
2006), Haploview (Barrett et al., 2005), and PBAT (Lange et al., 2004) are most commonly used 
in GWAS as can be gleaned from the literature. Both case-control and association study designs 
may be employed for a GWAS; however, case-control studies have been more popular and 
careful selection of matched controls with a particular focus on the ancestry has been 
recommended. Finally, the quality of the data used for analysis determines the accuracy with 
which any results from a GWAS may be used to draw conclusions. Neale and Purcell (2007) 
point to the following important issues – 
 Prior probability of a SNP showing true significance is rather low (5x10-7 is the 
accepted GWAS significance as set up by the Wellcome Trust Consortium). 
 A good indicator of genotype probe performance is the call rate across the sample. 
Call rates in excess of 85% are the expected norms used in GWAS. 
 Genotype reproducibility is another key measure assessed through international 
sample duplication. 
 Potential batch effects arise since samples (DNA sources) are not done with the same 
product at the same time. 
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 Minor allele frequency (MAF) thresholds are recommended (usually 1%) as many 
studies do not have the power to detect significant association for very rare variation. 
 Testing for deviations from the Hardy-Weinberg equilibrium (HWE) or, more aptly, 
Hardy-Weinberg proportions (Elston et al., 2010) may provide further information 
about the validity of the genotypes from a SNP. A stringent threshold of 10
-6
 for 
deviation from HWE is recommended to assure data quality. 
 Nonpaternity is a potential problem for family-based data when trio (i.e., patient and 
his or her parents) and sibship (i.e., patient and his or her siblings) designs are 
employed. 
 Population stratification is a confounding factor in case-control, population based 
quantitative analysis. A correction for the inflated association may be applied using 
the principal component analysis (Price et al., 2006). 
 The distribution of association of test statistics is a useful indicator for sources of 
biases.  
Further data cleaning considerations are available from the literature (Chanock et al., 2007; 
Wellcome Trust Case Control Consortium, 2007). GWAS gives one the most extensive looks at 
the genome for uncovering variations of disease predisposal, while not necessarily pointing the 
new biochemical pathways leading to a complex and multifactorial disease. Given the difficulty 
of mapping the genetic variants of neuropsychiatric disease such as MDD, any GWAS for MDD 
and related disorders must be carried out with even greater care. 
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Phenomics and Epigenomics  
Phenomics is another emerging transdiscipline where phenotypes are systematically studied 
on a genome-wide scale (Bilder et al., 2009). In the context of public health, phenomics research 
might be useful to relate neural systems functioning to human behavior. One of the advantages of 
studying phenotypes from a genome-wide perspective might be to generate phenotypes, not from 
a conventional laboratory or a web-based assessment of behavior, but rather, by iteratively 
refining phenotype assays based on prior genotype-phenotype associations. Vertically integrated 
research teams, novel analytic strategies, and the informatics infrastructure may help phenomics 
research in managing the sheer complexity involved in this sequel to genomics. Indeed, one of 
the nine interdisciplinary research consortia supported by NIH Roadmap Initiative that started in 
2007 is funding the phenomics research at UCLA to investigate two cognitive phenotypes 
(Bilder et al., 2009). 
 In addition to phenomics, yet another area of new research is epigenomics, the science of 
how genes might be modified by the environment while not changing the DNA sequence but still 
affecting the gene expression by affecting the chromatin structure, packaging, methylation, and 
other molecular modifications (Mehler, 2008). This is very important in understanding neuro-
degenerative diseases such as schizophrenia, bipolar disorder, and other brain developmental (or 
neural regenerative) and/or evolutionary mechanisms. Further insights into these new research 
areas are the subject of NIH roadmap for the future aiming to develop epigenome-wide analysis 
as a staple of future biological characterization. Further details are available at the NIH roadmap 
web site - http://nihroadmap.nih.gov/epigenomics/initiatives.asp. Some researchers are even 
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calling these initiatives as the beginnings of the Human Phenome Project promising to realize the 
vision of personalized medicine and rational neuropsychiatric diagnosis and treatment (Bilder et 
al., 2009).  
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APPENDIX C 
Additional Descriptive Histograms and Plots of Selected MDD Predictors 
Figure 4 and Figure 5 below show the univariate and Gene x Gender analyses of neuroticism 
scores in our sample population. 
 
Figure 4. Distribution of Mean Neuroticism Scores 
 
Figure 5. Gene x Gender Interaction in Neuroticism Scores
Mean Neuroticism Total Scores for the genotypes of 
the SNP – rs220549. 
Mean Neuroticism Total Scores for the genotypes of 
the SNP – rs4806846. 
Gene x Gender Interaction of Neuroticism Total 
Score for the SNP rs17674783 in SNTG1. 
Gene x Gender Interaction of Neuroticism Total 
Score for the SNP rs2430132 in HMCN1. 
    
134 
 
APPENDIX D 
Supplementary Tables from GWAS Studies of Neuroticism and Age at Onset 
 
Table D-1 
Genome-Wide Association Study Results of 34 Significant SNPs for Neuroticism in MDD
*
 
CHR 
Reference 
SNP 
Position
a 
Gene Name
 
Gene 
Location
 
P-value 
Total
b 
P-value 
Male
c 
P-value 
Female
d 
19 rs4806846 2361484 TMPRSS9 19p13.3 7.79E-06 0.001109 0.002405 
12 rs220549 13828587 GRIN2B 12p12 1.05E-05 0.05337 0.0002437 
17 rs1046329 45603905 SGCA  17q21  1.37E-05 0.1835 2.88E-05 
2 rs6757820 147996163 ACVR2A  2q22.3 1.51E-05 0.003489 0.002758 
6 rs4510687 96219582 
 (MANEA & 
FUT9) 
6q16.1  2.49E-05 0.1229 0.0001593 
3 rs985280 64083893 PSMD6 3p14.1 2.61E-05 0.07875 0.0009192 
6 rs4342432 96195874     2.96E-05 0.1475 0.0001645 
16 rs9807002 26184920     3.05E-05 0.1409 0.000289 
14 rs9323020 21228477 
Near 
EDDM3B 
14q11.2 3.29E-05 0.06499 0.0001355 
17 rs8068962 9254866 STX8 17p12 3.32E-05 0.05502 0.001416 
2 rs2344734 152400075 NEB 2q22 3.61E-05 0.1872 0.0005467 
2 rs12620464 101396078     4.09E-05 0.04817 0.0006929 
8 rs1608361 123732642 
LOC1001315
52 
8q24.13 4.13E-05 0.08719 0.004728 
2 rs10930046 162846229     4.68E-05 0.06334 0.001034 
5 rs6894463 3266546     4.81E-05 0.001539 0.003872 
17 rs2301685 32452234     4.94E-05 0.1001 0.002558 
20 rs6065392 39870080 ZHX3 20q12 5.02E-05 0.06333 0.001298 
11 rs10835855 32165526     5.15E-05 0.06333 0.001298 
8 rs16915079 51685259 
Near 
CYCSP22 
8q11.22 5.54E-05 0.03473 0.006221 
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Table D-1 (Continued) 
3 rs9834457 69604258 
Near 
LOC642487 
3p14.1 6.10E-05 0.02482 0.000309 
9 rs4837349 131024550 GOLGA2 9q34.11 6.42E-05 0.04986 0.0004275 
6 rs12198780 7501543 RPS26P29 6p24.3 6.53E-05 0.05282 0.002184 
8 rs4871135 121924955   7.33E-05 0.1549 0.0005861 
9 rs4740720 3196279   7.63E-05 0.4673 0.0003664 
9 rs4836644 131024527 GOLGA2 9q34.11 8.00E-05 0.08905 0.0002971 
5 rs298024 58977433   8.02E-05 0.05118 0.006706 
17 rs17651665 32419258 TLK2P1 17q12 8.43E-05 0.122 0.003107 
1 rs6702388 163236984   8.49E-05 0.01127 0.0007732 
23 rs6525630 144651865 LOC347422 Xq27.3 8.67E-05 0.03364 0.1668 
13 rs1927860 52964897 THSD1 13q14.3 9.23E-05 0.2213 0.001113 
18 rs8096705 39769843   9.30E-05 0.01499 0.02828 
8 rs7013587 52954726 ST18 8q11.23 9.53E-05 0.0183 0.07478 
8 rs7818832 52856493   9.70E-05 0.0235 0.07048 
23 rs5930284 127728822   9.97E-05 0.007143 0.1926 
*
 CHR = Chromosome Number; SNP = Single Nucleotide Polymorphism 
a
 Physical position is based on NCBI genome build 36.3. 
b
 Wald test asymptotic P-value for the association of neuroticism with MDD in the total sample. 
c
 Wald test asymptotic P-value for the association of neuroticism with MDD in the male sample. 
d
 Wald test asymptotic P-value for the association of neuroticism with MDD in the female sample. 
 
Table D-2 
Genome-Wide Association Study Results of 46 Significant SNPs for Gene x Gender Interaction of 
Neuroticism
*
 
 
CHR 
Reference 
SNP 
Gene Name 
Gene 
Location 
P-assoc 
Total
a 
P-assoc 
Male
b 
P-assoc 
Female
c P_GxE 
1 rs2430132 HMCN1 
1q25.3-
q31.1 
0.351 0.4283 0.6643 5.37E-06 
8 rs17674783 SNTG1 8q11-q12 0.8544 0.5047 0.999 6.92E-06 
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Table D-2 (Continued) 
17 rs2612437 
(MAP2K4 & 
MYOCD)  
0.9471 0.526 0.5177 9.30E-06 
12 rs11614157 
(PRP1R12A & 
C12orf64)  
0.0612 0.3835 0.2374 1.48E-05 
4 rs244052 ENPEP 4q25 0.2467 0.9248 0.4139 1.53E-05 
8 rs391798 SNTG1 8q11-q12 0.9659 0.483 0.8758 1.53E-05 
4 rs13146994 ATP8A1 4p14-p12 0.3128 0.2118 0.4046 1.66E-05 
20 rs6072394 
  
0.2119 0.9787 0.3763 1.77E-05 
3 rs9834626 RPL10AP6 3p14.2 0.6774 0.454 0.5157 1.78E-05 
15 rs870335 SMAD3 15q22.33 0.9354 0.4891 0.411 2.28E-05 
20 rs2326424 ADRA1D 20p13 0.04644 0.01311 0.2266 2.69E-05 
14 rs17111534 LOC100288480 14q11.2 0.3991 0.9245 0.1688 2.78E-05 
2 rs12692083 ISCA1P6 2q14.3 0.7659 0.2809 0.09403 2.83E-05 
15 rs2415037 SMAD3 15q22.33 0.8592 0.5387 0.4015 3.00E-05 
15 rs1532758 SMAD3 15q22.33 0.2269 0.973 0.07676 3.50E-05 
8 rs1023979 
  
0.2049 0.377 0.5902 3.65E-05 
6 rs11970411 TNFA1P3 6q23 0.9345 0.8628 0.8696 3.66E-05 
5 rs6595727 
  
0.1771 0.02356 0.9237 3.68E-05 
8 rs4412393 
  
0.6117 0.06589 0.3106 3.75E-05 
8 rs7832224 EFR3A 8q24.22 0.2561 0.8041 0.2023 4.21E-05 
8 rs203929   0.4532 0.9125 0.7004 4.25E-05 
8 rs12541061   0.1925 0.3405 0.5777 4.28E-05 
8 rs12478804 B3GALT1 2q24.3 0.05783 0.8438 0.3738 4.73E-05 
2 rs12480036   0.2312 0.9315 0.4074 4.73E-05 
8 rs203953   0.7064 0.7489 0.9391 4.79E-05 
8 rs12543181   0.2308 0.2388 0.1487 5.11E-05 
13 rs3905070 EFNB2 13q33 0.06431 0.2778 0.1601 5.44E-05 
15 rs2946543 SYNGR2P1 15q13.2 0.3641 0.731 0.592 5.54E-05 
1 rs11163755   0.6195 0.1876 0.3995 5.72E-05 
8 rs2942805   0.786 0.7985 0.436 5.73E-05 
18 rs10502673 GALNT1 18q12.1 0.05579 0.007379 0.1413 5.74E-05 
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Table D-2 (Continued) 
15 rs11539519   0.7383 0.0272 0.1347 5.76E-05 
5 rs6555484 ADCY2 5p15.3 0.1239 0.8236 0.01417 5.92E-05 
3 rs2717294 ALG3 3q27.1 0.04133 0.4183 0.03417 6.02E-05 
2 rs10194273   0.912 0.5944 0.8303 6.34E-05 
8 rs4623452   0.8869 0.06411 0.1713 6.92E-05 
17 rs7213039 TTLL6 17q21.32 0.2436 0.2449 0.7986 7.76E-05 
4 rs3829753 DUX4C  4q35.2 0.6033 0.4975 0.7407 7.94E-05 
8 rs1821122   0.169 0.2281 0.3058 8.02E-05 
13 rs1325396   0.4129 0.5374 0.07007 8.28E-05 
19 rs8112887   0.3088 0.7539 0.5337 8.31E-05 
17 rs7209419 TTLL6 17q21.32 0.2892 0.2922 0.8286 8.37E-05 
8 rs3104997   0.06863 0.06077 0.3434 8.54E-05 
4 rs4532257 TN1P3 4q27 0.4698 0.4746 0.5356 8.68E-05 
11 rs2457249 MIR708  11q14.1 0.3407 0.5289 0.1679 8.82E-05 
3 rs1685442   0.8079 0.6051 0.2961 9.03E-05 
 
*
 CHR = Chromosome Number; SNP = Single Nucleotide Polymorphism; MDD = Major Depressive 
Disorder; 
a, b, c
 Wald test asymptotic P-value for the association of neuroticism with MDD in the total, male, and 
female sample. 
 
Table D-3 
Genome-Wide Association Study Results of All Significant SNPs for ASPD in the Region of 
Implicated Genes for Neuroticism
*
 
 
CHR 
Reference 
SNP 
Gene 
Name 
P-Neoneu 
Total
a 
P-
Neoneu 
Male
b 
P-
Neoneu 
Female
c 
P-
MDD-
total
d 
P-
MDD-
male
e 
P-
MDD-
female
f 
OZ-
ASPD 
p-
value
g 
19 rs4806846 TMPRSS9 7.79E-06 0.0011 0.0024 0.002 0.061 0.0185 N/A 
19 rs4453628 TMPRSS9 N/A N/A N/A N/A N/A N/A 0.0538 
12 rs220549 GRIN2B 1.05E-05 0.0534 0.0002 0.055 0.971 0.0145 0.2521 
12 rs1158541 GRIN2B N/A N/A N/A N/A N/A N/A 0.0577 
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Table D-3 (Continued) 
12 rs2192973 GRIN2B N/A N/A N/A N/A N/A N/A 0.0624 
12 rs11055608 GRIN2B 0.9412 0.8302 0.5511 0.759 0.348 0.2884 0.0671 
12 rs2216127 GRIN2B 0.0824 0.4308 0.0798 0.039 0.105 0.1781 0.0484 
12 rs7974275 GRIN2B 0.865 0.9641 0.4977 0.461 0.757 0.2365 0.0194 
14 rs9323020 EDDM3B 3.29E-05 0.0650 0.0001 0.008 0.234 0.0173 0.2237 
14 rs10146821 OR10G2 0.0871 0.0701 0.7192 0.568 0.319 0.8758 0.0417 
14 rs10483255 
RANBP20
P 
N/A N/A N/A N/A N/A N/A 0.0269 
14 rs2874103 OR4E2 0.1635 0.8785 0.0596 0.223 0.329 0.3568 0.0802 
14 rs970382 OR4E2 0.1826 0.8555 0.0638 0.225 0.305 0.3741 0.0901 
14 rs6571990 EDDM3A N/A N/A N/A N/A N/A N/A 0.0028 
14 rs8013476 
LOC1002
87557 
N/A N/A N/A N/A N/A N/A 0.0735 
14 rs718433 RNASE1 0.7877 0.6430 0.5419 0.841 0.732 0.5755 0.0573 
14 rs2141971 RNASE1 0.7169 0.2254 0.3192 0.397 0.778 0.1487 0.0045 
17 rs8068962 STX8 3.32E-05 0.0550 0.0014 0.013 0.297 0.0156 N/A 
17 rs7216692 STX8 N/A N/A N/A N/A N/A N/A 0.0707 
17 rs6503203 STX8 N/A N/A N/A N/A N/A N/A 0.0453 
17 rs9904459 STX8 N/A N/A N/A N/A N/A N/A 0.0661 
17 rs7209802 STX8 N/A N/A N/A N/A N/A N/A 0.0295 
17 rs4791838 STX8 N/A N/A N/A N/A N/A N/A 0.0014 
17 rs3891720 STX8 N/A N/A N/A N/A N/A N/A 0.0224 
2 rs2344734 NEB 3.61E-05 0.1872 0.0005 0.076 0.789 0.0279 N/A 
8 rs16915079 CYCSP22 5.54E-05 0.0347 0.0062 0.066 0.306 0.1175 N/A 
8 rs12375352 SNTG1 N/A N/A N/A N/A N/A N/A 0.0781 
*
 CHR = Chromosome Number; SNP = Single Nucleotide Polymorphism; MDD = Major Depressive 
Disorder; ASPD = Anti-Social Personality Disorder. 
a, b, c
 Wald test asymptotic P-value for the association of neuroticism with MDD in the total, male, and 
female sample. 
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d, e, f
 Wald test asymptotic P-value for the association with MDD in the total, male, and female sample. 
g
 Wald test asymptotic P-value for the association with ASPD in the OZALC sample. 
 
 
Table D-4 
Genome-Wide Association Study Results of All Significant SNPs for Age at Onset of MDD
* 
 
CHR 
Reference 
SNP 
Gene Name 
Gene 
Location 
P-MDD-
Total
a 
P-MDD-
Male
b 
P-MDD-
Female
c 
P-
Neoneu
d 
P-
AAO
e 
23 rs734253 GPR143 Xp22.3 0.3747 N/A 0.8116 0.2357 
2.54E-
12 
23 rs6641545 ASS1P4 Xp22.33 0.7671 0.2733 0.2551 0.64 
9.75E-
10 
23 rs5983118 MXRA5 Xp22.33 0.398 N/A 0.1451 0.5025 
5.67E-
08 
23 rs17267483 HDX Xq22.1 0.4358 0.01471 0.7501 0.1034 
1.59E-
07 
23 rs5971527 CXorf29 Xp21.2 0.8627 0.01623 0.09991 0.6139 
1.70E-
07 
23 rs6654462 N/A N/A 0.3369 0.7451 0.1007 0.1432 
3.99E-
07 
23 rs5928558 
ENSG000002
33571 
N/A 0.04561 0.05098 0.1785 0.02767 
5.45E-
07 
23 rs6629704 PTCHD1 Xp22.11 0.603 0.3504 0.3814 0.02766 
1.01E-
06 
23 rs2490768 ZCCHC16 Xq23 0.03009 0.961 0.0249 0.9888 
4.17E-
06 
5 rs32589 PPARGC1B 5q32 0.7074 0.00509 0.01677 0.5262 
4.72E-
06 
23 rs5918490 SRPX Xp21.1 0.00262 0.9286 0.00181 0.3342 
4.97E-
06 
23 rs5935125 ARHGAP6 Xp22.3 0.07788 0.00667 0.5328 0.01839 
5.38E-
06 
23 rs17343481 
ENSG000002
38327 
N/A 0.7615 0.3565 0.5175 0.1023 
5.40E-
06 
6 rs9294523 RPL5P19 6q15 0.5052 0.09523 0.04591 0.6942 
5.83E-
06 
23 rs12393485 N/A N/A 0.439 0.01915 0.7968 0.4857 
5.92E-
06 
23 rs1468422 NDUFA1 Xq24 0.848 0.2351 0.5242 0.00049 
7.46E-
06 
5 rs10515638 PPARGC1B 5q32 0.8893 0.01328 0.1193 0.2302 
9.77E-
06 
5 rs26125 PPARGC1B 5q32 0.494 0.00681 0.00659 0.5332 
1.04E-
05 
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Table D-4 (Continued) 
23 rs3861732 
LOC1001286
01 
Xq22.1 0.6901 0.1144 0.1834 0.9338 
1.06E-
05 
23 rs17219420 HDX Xq21.1 0.6002 0.04163 0.6945 0.153 
1.25E-
05 
23 rs7883591 ZCCHC16 Xq23 0.2569 0.4755 0.1334 0.7061 
1.32E-
05 
23 rs5939057 ZCCHC16 Xq23 0.284 0.5247 0.1672 0.6689 
1.34E-
05 
5 rs17110375 PPARGC1B 5q32 0.62 0.07167 0.06859 0.07791 
1.42E-
05 
23 rs16980772 SCML2 Xp22 0.5505 0.04284 0.1247 0.6471 
1.65E-
05 
23 rs12846646 SAT1 Xp22.11 0.6008 0.2697 0.8674 0.1614 
1.69E-
05 
23 rs17245924 N/A N/A 0.05341 0.02078 0.2747 
0.00014
9 
1.73E-
05 
23 rs4562492 
ENSG000002
38327 
N/A 0.873 0.4318 0.9855 0.1903 
2.27E-
05 
23 rs11092550 NRK Xq22.3 0.2293 0.9968 0.2005 0.8261 
2.37E-
05 
23 rs5909462 SCML2 Xp22 0.5655 0.01616 0.07903 0.4144 
2.53E-
05 
23 rs17301374 CCT4P2 Xq11.2 0.04026 0.8737 0.02666 0.7771 
2.68E-
05 
23 rs5909169 SCML2 Xp22 0.4384 0.07897 0.1091 0.735 
2.78E-
05 
23 rs1500725 IL1RAPL1 
Xp22.1-
p21.3 
0.8097 0.08988 0.3676 0.9017 
3.10E-
05 
23 rs4378112 SHC1P1 Xq11.1 0.3433 0.376 0.1647 0.7435 
3.23E-
05 
6 rs6570806 N/A N/A 0.1601 0.08379 0.01287 0.8842 
3.23E-
05 
23 rs5970992 DDX53- Xp22.11 0.5179 0.015 0.05175 0.7221 
3.27E-
05 
8 rs16938568 RDH10 8q21.11 0.6015 0.1612 0.9382 0.1362 
3.36E-
05 
12 rs11107320 
LOC1001321
26 
12q22 0.4294 0.2577 0.1283 0.1142 
3.41E-
05 
11 rs3016415 GRIK4 11q22.3 0.6102 0.01755 0.02508 0.8042 
3.50E-
05 
6 rs10947795 KCNK16 
6p21.2-
p21.1 
0.5245 0.01124 0.4695 0.2657 
3.71E-
05 
22 rs34074034 TTLL12 22q13.31 0.2529 0.01343 0.9774 0.4047 
3.85E-
05 
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23 rs35401330 BEND2 Xp22.13 0.3709 0.05472 0.06403 0.5005 
3.89E-
05 
5 rs11738269 CANX 5q35 0.8539 0.02931 0.1304 0.2636 
3.95E-
05 
6 rs1876155 SIM1 
6q16.3-
q21 
0.1498 0.06722 0.5046 0.9709 
3.97E-
05 
23 rs590779 MIR514-3 Xq27.3 0.7882 0.1753 0.8695 0.745 
3.99E-
05 
15 rs11630901 RPAP1 15q15.1 0.1481 0.00367 0.9168 0.5768 
4.07E-
05 
23 rs4279777 FRMPD4 Xp22.2 0.699 0.02068 0.4697 0.28 
4.37E-
05 
23 rs989059 EDA 
Xq12-
q13.1 
0.9774 0.1451 0.4568 0.1792 
4.45E-
05 
8 rs17211245 RDH10 8q21.11 0.3178 0.1653 0.6283 0.03658 
4.70E-
05 
11 rs4573685 GRIK4 11q22.3 0.8897 0.02289 0.09412 0.2065 
5.02E-
05 
23 rs4824251 MIR514-3 Xq27.3 0.4736 0.2621 0.1843 0.53 
5.27E-
05 
23 rs5907414 N/A N/A 0.3992 0.3598 0.5648 0.05666 
5.40E-
05 
23 rs5927283 LOC392439 Xp21.1 0.08112 0.00244 0.6162 0.01826 
5.64E-
05 
10 rs11018112 N/A N/A 0.8165 0.1413 0.311 0.4234 
5.64E-
05 
23 rs5987957 PLS3 Xq23 0.7859 0.8008 0.6477 0.317 
5.68E-
05 
23 rs7472960 ZCCHC16 Xq23 0.2121 0.03187 0.6583 0.4743 
5.77E-
05 
23 rs2266835 MAMLD1 Xq28 0.1681 0.1089 0.3787 0.2941 
5.79E-
05 
9 rs870186     0.6415 0.2125 0.2563 0.781 
5.85E-
05 
10 rs10824745 LOC283050 10q22.3 0.7293 0.04759 0.08453 0.7109 
6.25E-
05 
23 rs1076616 N/A N/A 0.1157 0.2694 0.02248 0.3392 
6.30E-
05 
23 rs6635622 N/A N/A 0.7288 0.1708 0.3339 0.06482 
6.61E-
05 
6 rs885463 
LOC1001279
00 
6q13 0.2756 0.02632 0.00426 0.3531 
6.73E-
05 
1 rs10888527 ZNF687 1q21.3 0.3616 0.01012 0.00621 0.2164 
7.28E-
05 
23 rs7883119     0.4177 0.01898 0.8102 0.6838 
7.53E-
05 
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Table D-4 (Continued) 
11 rs4617622 LOC120364 11q23.1 0.8802 0.0819 0.3866 0.07239 
7.56E-
05 
23 rs12687753 RRM2P3 Xp11.4 0.3099 0.2069 0.08466 0.2026 
7.88E-
05 
23 rs5933909 ARHAGAP6 Xp22.3 0.05047 
0.00654
7 
0.3721 
0.00349
8 
7.89E-
05 
20 rs397883 TBC1D20 20p11.21 0.3593 0.01551 0.5936 0.5771 
8.07E-
05 
23 rs1476012 ALAS2 Xp11.21 0.36 0.3883 0.1781 0.7389 
8.22E-
05 
23 rs222108 KLHL4 Xq21.3 0.5008 0.06171 0.8959 0.8097 
8.37E-
05 
16 rs8048267 ZFHX3 16q22.3 0.2389 0.03201 
0.00284
5 
0.5397 
8.37E-
05 
8 rs7837426 RDH10 8q21.11 0.4974 0.2174 0.8439 0.02799 
8.49E-
05 
2 rs13394360 N/A N/A 0.4401 0.3643 0.1471 0.8868 
8.90E-
05 
5 rs17617710 CANX 5q35 0.9256 0.02371 0.2289 0.4248 
9.31E-
05 
23 rs5972323 DMD Xq34 0.2193 0.05967 0.5964 0.01431 
9.32E-
05 
23 rs5984014 N/A N/A 0.3235 0.1835 0.09834 0.8646 
9.81E-
05 
5 rs6895902 CANX 5q35 0.7987 0.0295 0.3488 0.338 
9.91E-
05 
 
*
 CHR = Chromosome Number; SNP = Single Nucleotide Polymorphism; MDD = Major Depressive 
Disorder; 
a, b, c
 Wald test asymptotic P-value for the association with MDD in the total, male, and female sample. 
d
 Wald test asymptotic P-value for the association of neuroticism with MDD in the total sample. 
e
 Wald test asymptotic P-value for the association of age at onset with MDD in the total sample. 
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